KR102061387B1 - Cosmetic composition for improving atopic dermatitis comprising Lactobacillus rhamnosus and conjugated linoleic acid - Google Patents
Cosmetic composition for improving atopic dermatitis comprising Lactobacillus rhamnosus and conjugated linoleic acid Download PDFInfo
- Publication number
- KR102061387B1 KR102061387B1 KR1020160035879A KR20160035879A KR102061387B1 KR 102061387 B1 KR102061387 B1 KR 102061387B1 KR 1020160035879 A KR1020160035879 A KR 1020160035879A KR 20160035879 A KR20160035879 A KR 20160035879A KR 102061387 B1 KR102061387 B1 KR 102061387B1
- Authority
- KR
- South Korea
- Prior art keywords
- milk
- skin
- weight
- atopic dermatitis
- lactobacillus rhamnosus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 133
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 title claims abstract description 117
- JBYXPOFIGCOSSB-GOJKSUSPSA-N 9-cis,11-trans-octadecadienoic acid Chemical compound CCCCCC\C=C\C=C/CCCCCCCC(O)=O JBYXPOFIGCOSSB-GOJKSUSPSA-N 0.000 title claims abstract description 114
- 229940108924 conjugated linoleic acid Drugs 0.000 title claims abstract description 114
- 241000218588 Lactobacillus rhamnosus Species 0.000 title claims abstract description 98
- 201000008937 atopic dermatitis Diseases 0.000 title claims abstract description 88
- 206010012438 Dermatitis atopic Diseases 0.000 title claims abstract description 83
- 239000002537 cosmetic Substances 0.000 title claims abstract description 45
- 238000001704 evaporation Methods 0.000 claims abstract description 33
- 230000008020 evaporation Effects 0.000 claims abstract description 33
- 230000014759 maintenance of location Effects 0.000 claims abstract description 29
- 241000191967 Staphylococcus aureus Species 0.000 claims abstract description 14
- 239000004480 active ingredient Substances 0.000 claims abstract description 13
- 230000003247 decreasing effect Effects 0.000 claims abstract description 11
- 239000008267 milk Substances 0.000 claims description 133
- 210000004080 milk Anatomy 0.000 claims description 133
- 235000013336 milk Nutrition 0.000 claims description 130
- 239000006071 cream Substances 0.000 claims description 106
- 238000009472 formulation Methods 0.000 claims description 77
- 239000006210 lotion Substances 0.000 claims description 70
- 235000020183 skimmed milk Nutrition 0.000 claims description 28
- 235000021243 milk fat Nutrition 0.000 claims description 26
- 239000000243 solution Substances 0.000 claims description 24
- 239000001963 growth medium Substances 0.000 claims description 21
- 238000002360 preparation method Methods 0.000 claims description 21
- 230000002401 inhibitory effect Effects 0.000 claims description 20
- 230000006872 improvement Effects 0.000 claims description 12
- 239000000839 emulsion Substances 0.000 claims description 10
- 230000005764 inhibitory process Effects 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 9
- 239000000843 powder Substances 0.000 claims description 9
- 230000000844 anti-bacterial effect Effects 0.000 claims description 7
- 230000002265 prevention Effects 0.000 claims description 7
- 239000004094 surface-active agent Substances 0.000 claims description 6
- 239000000499 gel Substances 0.000 claims description 5
- 239000007921 spray Substances 0.000 claims description 5
- 235000013861 fat-free Nutrition 0.000 claims description 4
- 239000006072 paste Substances 0.000 claims description 4
- 239000000725 suspension Substances 0.000 claims description 4
- 239000000344 soap Substances 0.000 claims description 3
- 230000000699 topical effect Effects 0.000 claims description 3
- 230000004888 barrier function Effects 0.000 claims description 2
- 239000012141 concentrate Substances 0.000 claims description 2
- 235000004213 low-fat Nutrition 0.000 claims description 2
- 230000003902 lesion Effects 0.000 abstract description 48
- 230000000694 effects Effects 0.000 abstract description 28
- 208000010668 atopic eczema Diseases 0.000 abstract description 14
- 201000004624 Dermatitis Diseases 0.000 abstract description 13
- 230000001603 reducing effect Effects 0.000 abstract description 10
- 230000000845 anti-microbial effect Effects 0.000 abstract description 9
- 206010033733 Papule Diseases 0.000 abstract description 8
- 208000003251 Pruritus Diseases 0.000 abstract description 8
- 230000001684 chronic effect Effects 0.000 abstract description 7
- 230000002757 inflammatory effect Effects 0.000 abstract description 7
- 206010040882 skin lesion Diseases 0.000 abstract description 7
- 231100000444 skin lesion Toxicity 0.000 abstract description 7
- 206010012434 Dermatitis allergic Diseases 0.000 abstract description 5
- 230000036620 skin dryness Effects 0.000 abstract description 5
- 208000024799 Thyroid disease Diseases 0.000 abstract description 2
- 208000021510 thyroid gland disease Diseases 0.000 abstract description 2
- 210000003491 skin Anatomy 0.000 abstract 2
- 206010063045 Effusion Diseases 0.000 abstract 1
- 210000002615 epidermis Anatomy 0.000 abstract 1
- 238000000855 fermentation Methods 0.000 description 111
- 230000004151 fermentation Effects 0.000 description 111
- 230000007423 decrease Effects 0.000 description 28
- 230000001965 increasing effect Effects 0.000 description 20
- 238000012360 testing method Methods 0.000 description 18
- 238000011282 treatment Methods 0.000 description 17
- 230000008859 change Effects 0.000 description 16
- 206010003645 Atopy Diseases 0.000 description 14
- 239000003921 oil Substances 0.000 description 13
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 12
- -1 trachants Polymers 0.000 description 12
- 235000019198 oils Nutrition 0.000 description 11
- 238000012790 confirmation Methods 0.000 description 10
- 230000002829 reductive effect Effects 0.000 description 10
- 235000014113 dietary fatty acids Nutrition 0.000 description 9
- 239000000194 fatty acid Substances 0.000 description 9
- 229930195729 fatty acid Natural products 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 6
- 239000003995 emulsifying agent Substances 0.000 description 6
- 150000004665 fatty acids Chemical class 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 239000008169 grapeseed oil Substances 0.000 description 5
- 239000006872 mrs medium Substances 0.000 description 5
- 235000015097 nutrients Nutrition 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 230000036572 transepidermal water loss Effects 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 4
- 238000012258 culturing Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 239000011259 mixed solution Substances 0.000 description 4
- 150000003431 steroids Chemical class 0.000 description 4
- 239000000454 talc Substances 0.000 description 4
- 229910052623 talc Inorganic materials 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 239000001993 wax Substances 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 239000000919 ceramic Substances 0.000 description 3
- 239000010779 crude oil Substances 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 230000007613 environmental effect Effects 0.000 description 3
- 235000019197 fats Nutrition 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 235000020778 linoleic acid Nutrition 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 206010043778 thyroiditis Diseases 0.000 description 3
- 239000011787 zinc oxide Substances 0.000 description 3
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical group C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- 206010013786 Dry skin Diseases 0.000 description 2
- 206010015150 Erythema Diseases 0.000 description 2
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 241000186660 Lactobacillus Species 0.000 description 2
- 241000186605 Lactobacillus paracasei Species 0.000 description 2
- 239000004264 Petrolatum Substances 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 239000013566 allergen Substances 0.000 description 2
- 229960004784 allergens Drugs 0.000 description 2
- 229940125715 antihistaminic agent Drugs 0.000 description 2
- 239000000739 antihistaminic agent Substances 0.000 description 2
- 235000012216 bentonite Nutrition 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 235000015140 cultured milk Nutrition 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 231100000676 disease causative agent Toxicity 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000037336 dry skin Effects 0.000 description 2
- 210000003414 extremity Anatomy 0.000 description 2
- 230000036571 hydration Effects 0.000 description 2
- 238000006703 hydration reaction Methods 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 229910010272 inorganic material Inorganic materials 0.000 description 2
- 239000011147 inorganic material Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 229940039696 lactobacillus Drugs 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000011326 mechanical measurement Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 229940066842 petrolatum Drugs 0.000 description 2
- 235000019271 petrolatum Nutrition 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000000306 recurrent effect Effects 0.000 description 2
- 230000008591 skin barrier function Effects 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 150000005846 sugar alcohols Polymers 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 1
- FFJCNSLCJOQHKM-CLFAGFIQSA-N (z)-1-[(z)-octadec-9-enoxy]octadec-9-ene Chemical compound CCCCCCCC\C=C/CCCCCCCCOCCCCCCCC\C=C/CCCCCCCC FFJCNSLCJOQHKM-CLFAGFIQSA-N 0.000 description 1
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical class CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 1
- LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 description 1
- UIVPNOBLHXUKDX-UHFFFAOYSA-N 3,5,5-trimethylhexyl 3,5,5-trimethylhexanoate Chemical compound CC(C)(C)CC(C)CCOC(=O)CC(C)CC(C)(C)C UIVPNOBLHXUKDX-UHFFFAOYSA-N 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 102100039648 Lactadherin Human genes 0.000 description 1
- 101710191666 Lactadherin Proteins 0.000 description 1
- 241000186673 Lactobacillus delbrueckii Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 206010024438 Lichenification Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 241000238711 Pyroglyphidae Species 0.000 description 1
- 206010039509 Scab Diseases 0.000 description 1
- 206010040799 Skin atrophy Diseases 0.000 description 1
- 206010053262 Skin swelling Diseases 0.000 description 1
- 241000295644 Staphylococcaceae Species 0.000 description 1
- 108050007077 Staphylococcus aureus exotoxin Proteins 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000194020 Streptococcus thermophilus Species 0.000 description 1
- ULUAUXLGCMPNKK-UHFFFAOYSA-N Sulfobutanedioic acid Chemical compound OC(=O)CC(C(O)=O)S(O)(=O)=O ULUAUXLGCMPNKK-UHFFFAOYSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 229910021536 Zeolite Inorganic materials 0.000 description 1
- FMRLDPWIRHBCCC-UHFFFAOYSA-L Zinc carbonate Chemical compound [Zn+2].[O-]C([O-])=O FMRLDPWIRHBCCC-UHFFFAOYSA-L 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- BTFJIXJJCSYFAL-UHFFFAOYSA-N arachidyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCO BTFJIXJJCSYFAL-UHFFFAOYSA-N 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 230000009702 cancer cell proliferation Effects 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 229960004203 carnitine Drugs 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 229940106189 ceramide Drugs 0.000 description 1
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 150000005827 chlorofluoro hydrocarbons Chemical class 0.000 description 1
- 230000003749 cleanliness Effects 0.000 description 1
- 239000008199 coating composition Substances 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- HNPSIPDUKPIQMN-UHFFFAOYSA-N dioxosilane;oxo(oxoalumanyloxy)alumane Chemical compound O=[Si]=O.O=[Al]O[Al]=O HNPSIPDUKPIQMN-UHFFFAOYSA-N 0.000 description 1
- 238000002845 discoloration Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 239000000686 essence Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 229940044627 gamma-interferon Drugs 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 239000010440 gypsum Substances 0.000 description 1
- 229910052602 gypsum Inorganic materials 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- 229940046533 house dust mites Drugs 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical class C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 238000005470 impregnation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 229940100554 isononyl isononanoate Drugs 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000013081 microcrystal Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229940071089 sarcosinate Drugs 0.000 description 1
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 230000037380 skin damage Effects 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 239000000779 smoke Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000003319 supportive effect Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 235000008939 whole milk Nutrition 0.000 description 1
- 239000010457 zeolite Substances 0.000 description 1
- 239000011667 zinc carbonate Substances 0.000 description 1
- 229910000010 zinc carbonate Inorganic materials 0.000 description 1
- 235000004416 zinc carbonate Nutrition 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/361—Carboxylic acids having more than seven carbon atoms in an unbroken chain; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Dermatology (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Emergency Medicine (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Cosmetics (AREA)
Abstract
본 발명은 락토바실러스 람노서스(Lactobacillus rhamnosus) 배양액 및 공액리놀레산(conjugated linoleic acid)을 유효성분으로 함유하는 아토피 피부염(atopic dermatitis) 개선용 화장료 조성물에 관한 것으로, 구체적으로 본 발명의 조성물은 황색포도상구균에 대한 항균활성이 높을 뿐 아니라, 아토피 피부염에서 주로 나타나는 피부 건조증, 소양증, 습진 및 염증성 피부병변 및 아급성 병변인 삼출, 가피를 동반한 구진과 인설, 만성 병변인 태선화 등의 병변의 완화 및 재발의 억제효과와 이에 상응하는 알레르기성 피부염의 병변 완화와 피부수분보유량의 향상, 피부의 pH수치 감소, 경피수분증발량의 감소 효과를 나타내므로, 아토피 피부염 예방, 억제 및 개선용 화장료 조성물로 유용하게 사용될 수 있다.The present invention relates to a cosmetic composition for improving atopic dermatitis containing Lactobacillus rhamnosus culture and conjugated linoleic acid as an active ingredient, and specifically, the composition of the present invention is Staphylococcus aureus. In addition to its high antimicrobial activity, it also relieves and relapses such as skin dryness, pruritis, eczema and inflammatory skin lesions and subacute effusions, papules and papules with epidermis, and thyroid disease, chronic lesions. It is effective to prevent, suppress and improve atopic dermatitis because it shows the effect of suppressing and reducing the lesion of corresponding allergic dermatitis, improving skin moisture retention, decreasing skin pH value and transdermal moisture evaporation. Can be.
Description
본 발명은 락토바실러스 람노서스(Lactobacillus rhamnosus) 배양액 및 공액리놀레산(conjugated linoleic acid)을 유효성분으로 함유하는 아토피 피부염(atopic dermatitis) 예방, 억제 및 개선용 화장료 조성물, 및 피부 외용제에 관한 것이다.
The present invention relates to a cosmetic composition for preventing, inhibiting and improving atopic dermatitis containing Lactobacillus rhamnosus culture and conjugated linoleic acid as an active ingredient, and a skin external preparation.
아토피 피부염(atopic dermatitis)은 만성적이며 재발이 빈번한 염증성 피부질환이다. 피부건조증과 소양증, 이로 인해 긁게 되면 습진 및 염증성 피부병변이 생기며 이것이 진행되면서 더 심한 소양증 및 수면장애 등이 유발되는 악순환이 반복된다. 또한 초기에 적절한 관리를 하지 않으면 삼출과 가피를 동반한 홍반성의 박탈성 구진과 인설로 진행되기도 하고 피부가 두꺼워지고 주름이 지는 태선화(苔癬化, lichenification) 등으로 진행되기도 한다. 유아기에는 보통 목과 팔다리, 무릎 뒤 등의 굽혀지는 쪽 부분에 습진 형태로 나타나고 만성화되면 습진 부위 피부가 태선화가 진행되고, 성인기까지 아토피 피부염이 남는 경우에는 특정 물질이나 자극에 의해 쉽게 염증 반응에 노출되는 경향이 많고, 몸보다는 얼굴 주변이나 사지말단에 습진이 생기거나 홍반 및 홍조가 나타나는 경향이 있다.Atopic dermatitis is a chronic, recurrent inflammatory skin disease. Dry skin and pruritus, which causes scratches, cause eczema and inflammatory skin lesions, and as this progresses, a vicious cycle of more severe pruritus and sleep disorders occurs. In addition, if proper care is not taken in the early stages, erythematous deprivation papules and sulcus with exudation and skin may progress, and the skin may become thick and wrinkled, lichenification. In infancy, eczema usually appears on the bent part of the neck, limbs, back of the knee, etc., and when it becomes chronic, the eczema skin progresses to the lichen, and when atopic dermatitis remains until adulthood, it is easily exposed to inflammatory reactions by certain substances or stimuli. They tend to have a tendency to develop eczema or erythema and redness around the face or extremities rather than the body.
아토피 피부염은 유전 및 환경적 요인의 상호작용으로 인한 복합적 임상 증상으로 다양하게 나타나기 때문에 발병 원인이 어느 한 가지로만 설명될 수는 없으나, 매연 등의 환경 공해, 식품첨가물 등의 사용 증가, 실내 온도 상승으로 인한 집먼지 진드기 등의 알레르기를 일으키는 원인 물질(알레르겐)의 증가 등 환경적인 요인과 유전적인 소인, 면역학적 반응 및 피부보호막의 이상, 가족력 등이 주요 원인으로 여겨지고 있다.Atopic dermatitis is a complex clinical symptom due to the interaction of genetic and environmental factors. Therefore, the cause of the atopic dermatitis cannot be explained by any one, but the environmental pollution such as smoke, the use of food additives, the increase of room temperature, etc. Environmental factors such as increased allergens (allergens), such as house dust mites, are attributed to environmental predisposition, genetic predisposition, immunological reactions, skin barrier abnormalities, and family history.
황색포도상구균(Staphylococcus aureus)은 사람이나 동물의 피부표면에 생육하면서 화농성 염증 질환을 일으킬 뿐 아니라 아토피 피부염을 일으키는 주범이기도 하다. 아토피 피부염 환자의 대부분의 병변에서 황색포도상구균이 고밀도로 발견되어 황색포도상구균이 아토피 피부염의 악화를 가중시킨다고 한다. 실제로 황색포도상구균의 외독소가 확인된 환자들의 SCORAD 점수가 다른 이들보다 높을 뿐 아니라, 피부건조증, 태선화, 지지간 미란 등의 진행을 가속시킨다.Staphylococcus aureus ( Staphylococcus aureus ) is a major culprit of atopic dermatitis as well as purulent inflammatory disease as it grows on the skin surface of humans or animals. Staphylococcus aureus is found in high density in most lesions of patients with atopic dermatitis, which is said to aggravate atopic dermatitis. Indeed, patients with Staphylococcus aureus exotoxin not only have higher SCORAD scores than others, but also accelerate the progression of skin dryness, limbing, and supportive erosion.
종합적으로 아토피 피부염 환자는 피부장벽의 이상이 있어, 피부수분보유량이 감소하며, 피부의 pH 수치의 증가 및 경피수분증발량이 증가할 뿐 아니라, 아토피 피부염 병변에서 황색포도상구균의 집락수가 정상인에 비해 월등히 높다.
Overall, patients with atopic dermatitis have abnormal skin barriers, which reduce skin moisture retention, increase skin pH levels, and increase transdermal moisture evaporation, and significantly increase the number of Staphylococcus aureus colonies in atopic dermatitis lesions. high.
현재 아토피 피부염 환자의 임상 점수인 SCORAD(Scoring of Atopic Dermatitis), ADSI(Atopic Dermatitis Severity Index) 등으로 아토피 피부염의 중증도를 평가하며, 피부에 직접 기계장비를 이용하여 항온, 항습 등 일정한 조건하에서의 피부수분보유량(skin surface hydration, SSH), 피부의 pH, 경피수분증발량(transepidermal water loss, TEWL) 등을 측정함으로써 피부의 장벽 기능과 염증 상태 등의 피부손상지표를 객관적으로 평가한다.SCORAD (Scoring of Atopic Dermatitis) and ADSI (Atopic Dermatitis Severity Index) are used to evaluate the severity of atopic dermatitis, and the skin moisture under constant conditions such as constant temperature and humidity using the mechanical equipment directly on the skin. By measuring skin surface hydration (SSH), skin pH, transepidermal water loss (TEWL) and the like, skin damage indicators such as barrier function and inflammatory state of the skin are objectively evaluated.
아토피 피부염의 기본적인 치료로 피부의 청결과 건조 방지를 위해 보습제의 사용, 피부염증을 완화시키기 위해 경구용 항히스타민제, 스테로이드제, 면역억제제, 항생제, 항바이러스제, 항진균제, 생균제 등의 치료제제의 사용 및 광화학요법 등 무수히 많은 치료 요법을 사용하고 있으나, 이러한 제제를 장기간 사용 시 피부 위축 및 팽창, 혈관 및 모공 확장, 피부 변색 등의 부작용이 유발될 뿐 아니라, 아토피 피부염의 특성상 만성적이거나 재발을 자주하면서 질환에 대한 회의와 스테로이드제와 같은 약물의 부작용에 대한 우려도 커 제대로 된 치료가 이루어지지 못하거나, 검증되지 않은 치료 방법에 의존하여 결국 악화와 호전을 반복하는 만성질환이 되는 경우도 많다. 따라서, 부작용이 없고 인체에 안전한 천연물 유래 아토피 피부염 치료제가 꾸준히 요구되고 있는 실정이다.
As a basic treatment of atopic dermatitis, the use of moisturizers for the cleanliness and dryness of the skin, the use of oral antihistamines, steroids, immunosuppressants, antibiotics, antiviral agents, antifungal agents, probiotics, etc. Although numerous treatment regimens, such as photochemistry, are used, prolonged use of these preparations can cause side effects such as skin atrophy and swelling, expansion of blood vessels and pores, discoloration of the skin, and chronic or recurrent disease due to the nature of atopic dermatitis. Concerns about the side effects of drugs, such as steroids and steroids, are also largely unsuccessful, or rely on unproven treatments, resulting in chronic illnesses that eventually worsen and improve. Therefore, there is a steady demand for a natural dermatitis-derived therapeutic agent derived from natural products that are safe for humans.
1998년 미국에서 다이어트식품으로 처음 판매된 공액리놀레산(conjugated linoleic acid, CLA)은 linoleic acid와 동일하게 탄소수가 18개이며, 단일결합을 사이에 두고 2개의 이중결합이 존재하는 공액이중결합 형태의 불포화지방산이다. 공액리놀레산 복용 후 carnitine의 활동을 원활하게 하여 체지방 소모를 촉진하며, 암세포 증식을 억제하고 대식세포의 기능을 향상시켜 면역력을 증강시키거나 각 성인병 예방 등의 효능이 있다고 보고되었다.
Conjugated linoleic acid (CLA), first sold as a diet food in the United States in 1998, has the same 18 carbon atoms as linoleic acid, and is a conjugated double-bond unsaturated form with two double bonds between them. Fatty acids. It has been reported that after taking conjugated linoleic acid, carnitine activity is promoted to promote body fat consumption, inhibit cancer cell proliferation, enhance macrophage function, enhance immunity or prevent each adult disease.
유산균은 면역계내에서 마이크로파지를 활성화하여 세균이나 바이러스를 즉각 감지하는가 하면 림프구 분열을 촉진해 혈액내에서 IgA의 생산 증가, 감마 인터페론 생성 촉진 등으로 면역력을 증진시킨다. 실험동물과 배양세포를 중심으로 일부 유산균의 항알러지 효과가 나타나고 있고, 특히 아토피 피부염 중심으로 그의 효과가 입증되었다. 특히 유산균 배양액은 산성 피막을 얇게 형성해 보습성분과 함께 피부에 도포되는 경우 윤기를 부여하며 부드러운 감촉을 가지게 한다.Lactobacillus activates microphages in the immune system to immediately detect bacteria or viruses, and promotes lymphocyte division, thereby increasing immunity by increasing IgA production in the blood and promoting the production of gamma interferon. The anti-allergic effect of some lactic acid bacteria has been shown mainly in experimental animals and cultured cells, and especially in atopic dermatitis. In particular, lactic acid bacteria cultured to form a thin acidic film when applied to the skin with a moisturizing ingredient gives a soft and soft texture.
한편, 람노서스류를 경구 복용 시 알레르기를 완화시키는 능력이 있고 이로 인해 정장 효과가 있는 경우 피부염, 여드름, 아토피 피부염을 치료하는 데 효과가 있다고 수차례 보고된 바 있으며, 유산균종으로부터 2종 이상의 혼합균을 배양하여 얻은 배양액을 이용한 천연항균제 개발 등의 유산균 및 이의 배양액을 화장료 조성물 및 약제학적 조성물로 개발하고 일본의 경우 불가리아균(Lactobacillus delbrueckii subspecies bulgaricus) 및 서모필러스균(Streptococcus thermophilus)을 배양한 후 그 배양물을 콜라겐 펩티드나 세라미드를 함유하는 피부 개선용 발효유에 관한 연구도 진행되었다. 또한 최근 피부유래 람노서스와 락토바실러스 파라카제이(Lactobacillus paracasei)의 복합균주를 이용한 발효물질에 대한 기능성 화장료 조성물에 대한 연구가 보고된 바 있으나, 락토바실러스 람노서스(Lactobacillus rhamnosus) 배양액 및 공액리놀레산(conjugated linoleic acid)을 포함하는 혼합물의 현저한 아토피 피부염 개선 효과에 대해서는 전혀 알려진 바 없다.
On the other hand, it has been reported several times that it is effective in treating dermatitis, acne and atopic dermatitis if it has the ability to relieve allergies when taking oral ramnosus, and has a formal effect. Lactobacillus and its culture solution, such as the development of natural antimicrobial agents using culture medium obtained by culturing bacteria, were developed into cosmetic and pharmaceutical compositions, and in the case of Japan, Lactobacillus delbrueckii subspecies bulgaricus and Streptococcus thermophilus were cultured. Subsequently, studies were also conducted on fermented milk for skin improvement containing the collagen peptide and ceramide. In addition, a recent study on the functional cosmetic composition for the fermentation material using a complex strain of skin-derived Rhamnosus and Lactobacillus paracasei ( Lactobacillus paracasei ), but Lactobacillus rhamnosus culture and conjugated linoleic acid ( There is no known significant improvement in atopic dermatitis of mixtures containing conjugated linoleic acid.
이에, 본 발명자들은 인체에 안전하고 부작용이 없으며, 현저한 아토피 피부염 개선 효과를 갖는 화장료 조성물을 개발하기 위해 노력한 결과, 락토바실러스 람노서스 배양액과 공액리놀레산의 혼합액을 함유하는 아토피 피부염 개선용 화장료 조성물이 황색포도상구균에 대한 항균활성이 높을 뿐 아니라, 아토피 피부염에서 주로 나타나는 피부 건조증, 소양증, 습진 및 염증성 피부병변 및 아급성 병변인 삼출, 가피를 동반한 구진과 인설, 만성 병변인 태선화 등의 병변의 완화 및 재발의 억제효과와 이에 상응하는 알레르기성 피부염의 병변 완화와 피부수분보유량의 향상, 피부의 pH수치 감소, 경피수분증발량의 감소 효과의 기능이 있는 것을 확인함으로써 본 발명을 완성하게 되었다.
Accordingly, the present inventors have tried to develop a cosmetic composition that is safe for the human body and has no side effects, and has a remarkable effect of improving atopic dermatitis.As a result, the cosmetic composition for improving atopic dermatitis containing a mixture of Lactobacillus rhamnosus culture medium and conjugated linoleic acid is yellow. In addition to its high antibacterial activity against staphylococci, it also relieves lesions such as dry skin, pruritis, eczema and inflammatory skin lesions and subacute lesions, exudation of the skin, papules and sessile lesions, and thyroid disease. And the present invention was completed by confirming that there is a function of inhibiting the recurrence and corresponding alleviating lesions of allergic dermatitis, improving skin moisture retention, decreasing skin pH value, and reducing transdermal moisture evaporation.
본 발명의 목적은 락토바실러스 람노서스 배양액 및 공액리놀레산을 유효성분으로 함유하는 아토피 피부염 예방, 억제 및 개선용 화장료 조성물, 및 피부 외용제를 제공하기 위한 것이다.
An object of the present invention is to provide a cosmetic composition for preventing, inhibiting and improving atopic dermatitis, which contains Lactobacillus rhamnosus culture and conjugated linoleic acid as an active ingredient, and an external preparation for skin.
상기 목적을 달성하기 위하여, 본 발명은 락토바실러스 람노서스 배양액 및 공액리놀레산을 유효성분으로 함유하는 아토피 피부염 예방, 억제 및 개선용 화장료 조성물을 제공한다.In order to achieve the above object, the present invention provides a cosmetic composition for the prevention, inhibition and improvement of atopic dermatitis containing Lactobacillus rhamnosus culture solution and conjugated linoleic acid as an active ingredient.
또한, 본 발명은 락토바실러스 람노서스 배양액 및 공액리놀레산을 유효성분으로 함유하는 아토피 피부염 예방, 억제 및 개선용 피부 외용제를 제공한다.The present invention also provides a topical skin preparation for the prevention, inhibition and improvement of atopic dermatitis containing Lactobacillus rhamnosus culture and conjugated linoleic acid as an active ingredient.
또한, 본 발명은 락토바실러스 람노서스 균주를 포함하는 우유 발효액을 유효성분으로 함유하는 아토피 피부염 예방, 억제 및 개선용 화장료 조성물을 제공한다.The present invention also provides a cosmetic composition for preventing, inhibiting and improving atopic dermatitis, which contains a milk fermentation broth comprising Lactobacillus rhamnosus strain as an active ingredient.
아울러, 본 발명은 락토바실러스 람노서스 균주를 포함하는 우유 발효액을 유효성분으로 함유하는 아토피 피부염 예방, 억제 및 개선용 피부 외용제를 제공한다.
In addition, the present invention provides a skin external preparation for preventing, inhibiting and improving atopic dermatitis, which contains a milk fermentation broth including Lactobacillus rhamnosus strain as an active ingredient.
본 발명의 락토바실러스 람노서스 배양액 및 공액리놀레산의 혼합액을 함유하는 아토피 피부염 개선용 화장료 조성물은 황색포도상구균에 대한 항균활성이 높을 뿐 아니라, 아토피 피부염에서 주로 나타나는 피부 건조증, 소양증, 습진 및 염증성 피부병변 및 아급성 병변인 삼출, 가피를 동반한 구진과 인설, 만성 병변인 태선화 등의 병변의 완화 및 재발의 억제효과와 이에 상응하는 알레르기성 피부염의 병변 완화와 피부수분보유량의 향상, 피부의 pH수치 감소, 경피수분증발량의 감소 효과를 나타내므로, 아토피 피부염 예방, 억제 및 개선용 화장료 조성물로 유용하게 사용될 수 있다.
Cosmetic composition for improving atopic dermatitis containing a mixed solution of the Lactobacillus rhamnosus culture medium and conjugated linoleic acid of the present invention has high antibacterial activity against Staphylococcus aureus, as well as skin dryness, pruritus, eczema and inflammatory skin lesions that are mainly shown in atopic dermatitis. Inhibition of recurrence and recurrence of lesions such as exudation, subcutaneous papules and papules, and chronic lesions of thyroiditis, and corresponding reduction of allergic dermatitis, improvement of skin moisture retention, skin pH value Since the effect of reducing, reducing the amount of transdermal moisture evaporation, it can be usefully used as a cosmetic composition for preventing, inhibiting and improving atopic dermatitis.
도 1은 유크림(시료 A) 및 유크림 발효액(시료 B)의 지방산 검사 성적서를 나타낸 도이다.
도 2는 공액리놀레산이 2 중량%가 자체 함유되고 유지방이 35%이상 함유된 유크림 발효액의 아토피 피부염 치료효과를 확인한 도이다.
도 3은 락토바실러스 람노서스 균주의 항균활성을 확인한 도이다.1 is a diagram showing a fatty acid test report of milk cream (sample A) and milk cream fermentation broth (sample B).
2 is a diagram confirming the therapeutic effect of atopic dermatitis of the milk cream fermentation broth containing 2% by weight of conjugated linoleic acid itself and 35% or more milk fat.
3 is a diagram confirming the antimicrobial activity of Lactobacillus rhamnosus strain.
이하, 본 발명을 상세히 설명한다.
Hereinafter, the present invention will be described in detail.
본 발명은 락토바실러스 람노서스(Lactobacillus rhamnosus) 배양액 및 공액리놀레산(conjugated linoleic acid)을 유효성분으로 함유하는 아토피 피부염 예방, 억제 및 개선용 화장료 조성물을 제공한다.The present invention provides a cosmetic composition for the prevention, inhibition and improvement of atopic dermatitis, containing Lactobacillus rhamnosus culture and conjugated linoleic acid as an active ingredient.
상기 락토바실러스 람노서스 균주는 계통학적으로 락토바실러스 람노서스로 분류되는 균주인 것이 바람직하고, human face, human mouth 등 human 유래 및 milk, cheese 등 milk 유래의 락토바실러스 람노서스 균주인 것이 보다 바람직하며, 락토바실러스 람노서스 KCTC 5033, KCTC 3237, KCTC 5046, KCTC 5510, KCTC 10965BP, KCCM 11320, KCCM 32823, KCCM 32826, KCCM 40069, ATCC 9595, ATCC 14957, ATCC 21052 또는 RA-32인 것이 가장 바람직하나 이에 한정되지 않는다. The Lactobacillus rhamnosus strain is preferably systematically classified as Lactobacillus rhamnosus, more preferably from humans such as human face, human mouth, Lactobacillus rhamnosus strain derived from milk, such as milk, cheese, Lactobacillus rhamnosus KCTC 5033, KCTC 3237, KCTC 5046, KCTC 5510, KCTC 10965BP, KCCM 11320, KCCM 32823, KCCM 32826, KCCM 40069, ATCC 9595, ATCC 14957, ATCC 21052 or RA-32 It doesn't work.
상기 배양액은 락토바실러스 람노서스를 배양 배지에서 배양하여 수득한 배양액, 농축 배양액, 배양액의 건조물, 배양 여과액, 농축 배양 여과액, 또는 배양 여과액의 건조물을 의미하는 것으로, 상기 균주를 포함하는 것 또는 배양한 후 균주를 제거한 배양여액일 수 있다. 또한 상기 배양물은 그 제형이 한정되지 아니하고, 일 예로 액체, 에멀젼, 또는 고체일 수 있다.The culture medium refers to a culture solution obtained by culturing Lactobacillus rhamnosus in a culture medium, a concentrated culture medium, a dried product of the culture solution, a culture filtrate, a concentrated culture filtrate, or a dried product of the culture filtrate, and containing the strain. Or it may be a culture filtrate after the strain is removed. In addition, the culture is not limited in its formulation, and may be, for example, a liquid, an emulsion, or a solid.
상기 배양액은 락토바실러스 람노서스를 MRS 배지에 배양한 배양액, 또는 락토바실러스 람노서스를 우유 또는 유크림(milk cream)에 접종하여 배양한 배양액인 것이 바람직하다.The culture medium is preferably a culture medium in which Lactobacillus rhamnosus is cultured in MRS medium, or cultured by inoculating Lactobacillus rhamnosus with milk or milk cream.
상기 락토바실러스 람노서스를 우유 또는 유크림에 접종하여 배양한 배양액은 하기와 같이 제조되는 것이 바람직하나 이에 한정되지 않는다.Culture medium cultured by inoculating the Lactobacillus rhamnosus in milk or milk cream is preferably prepared as follows, but is not limited thereto.
1) 락토바실러스 람노서스를 전배양하는 단계;1) preculturing Lactobacillus rhamnosus;
2) 상기 전배양된 락토바실러스 람노서스 균주를 우유 또는 유크림에 접종하고 본 배양하여 배양액인 우유 발효액 또는 유크림 발효액을 제조하는 단계.2) inoculating the pre-cultivated Lactobacillus rhamnosus strain in milk or milk cream and culturing the culture to prepare a milk fermentation broth or milk cream fermentation broth.
상기 단계 1)의 전배양은 락토바실러스 람노서스 균주를 MRS 배지에서 배양한 것이 바람직하다.The pre-culture of step 1) is preferably cultured Lactobacillus rhamnosus strain in MRS medium.
상기 단계 2)의 우유는 무지방 우유 또는, 유지방 함량이 1 중량부 이하로 첨가된 저지방, 무지방 우유 또는 탈지유(skim milk)일 수 있고, 상기 유크림은 원유 또는 우유에서 분리한 유지방분을 가리키는 것으로(유지방분 30% 이상), 유지방구막(MFGM)에 의해 형성되는 유지방구의 농축물(크림층)이라 할 수 있다. 유크림의 영양분은 크림 분리 전인 원유의 영양분에 영향을 받으며, 수용성 영양분의 함량은 감소하는 반면 지용성 영양분(비타민A, D, E, K)들은 원유보다 적게는 2~3배, 많게는 12배 이상 증가한다고 알려져 있다.The milk of step 2) may be nonfat milk or low fat, nonfat milk or skim milk having a milk fat content of 1 part by weight or less, and the milk cream may be a milk fat separated from crude milk or milk. It can be said that it is the concentrate (cream layer) of the fat or oil fat formed by the fat or oil discharge film (MFGM). Milk cream's nutrients are affected by the nutrients of crude oil before cream separation, while the content of water-soluble nutrients decreases, while fat-soluble nutrients (vitamins A, D, E and K) are two to three times less than crude oil and as many as 12 times more than crude oil. It is known to increase.
상기 단계 2)의 배양은 25 내지 35℃에서 1 내지 4일 배양하는 것이 바람직하고, 상온에서 24시간 배양하는 것이 바람직하나 이에 한정되는 것은 아니다.The culture of step 2) is preferably incubated for 1 to 4 days at 25 to 35 ℃, it is preferable to incubate at room temperature for 24 hours, but is not limited thereto.
상기 락토바실러스 람노서스 배양액은 전체 100 중량부에 대하여, 0.1 내지 99.9 중량부, 30 내지 90 중량부, 40 내지 80 중량부, 70 내지 80 중량부일 수 있다. 또한, 상기 공액리놀레산은 전체 100 중량부에 대하여, 0.1 내지 99.9 중량부, 1.5 내지 70 중량부, 15 내지 60 중량부, 20 내지 30 중량부일 수 있다. 다만, 락토바실러스 람노서스를 유지방 3%이하 함유된 우유에서 배양한 배양액일 경우에는 전체 100 중량부에 대하여, 0.04-99.9 중량부인 것이 바람직하다.The Lactobacillus rhamnosus culture may be 0.1 to 99.9 parts by weight, 30 to 90 parts by weight, 40 to 80 parts by weight, 70 to 80 parts by weight based on 100 parts by weight of the total. In addition, the conjugated linoleic acid may be 0.1 to 99.9 parts by weight, 1.5 to 70 parts by weight, 15 to 60 parts by weight, 20 to 30 parts by weight based on 100 parts by weight of the total. However, in the case of a culture solution cultured in milk containing 3% or less of lactobacillus rhamnosus, milk is preferably 0.04-99.9 parts by weight based on 100 parts by weight.
상기 화장료 조성물은 아토피 피부염의 정도를 판단하는 기준인 피부의 피부수분보유량의 향상, 피부의 pH수치 감소, 경피수분증발량의 감소 효과를 가지며, 아토피 피부염의 원인균인 황색포도상구균에 대한 항균 활성을 나타낸다.
The cosmetic composition has the effect of improving the skin moisture retention of the skin, the pH value of the skin, the decrease of transdermal moisture evaporation, which is a criterion for determining the degree of atopic dermatitis, and exhibits antimicrobial activity against Staphylococcus aureus, a causative agent of atopic dermatitis. .
본 발명의 구체적인 실시예에서, 본 발명자들은 락토바실러스 람노서스 배양액 및 공액리놀레산을 포함하는 로션 제형을 제조한 후, 상기 제형의 피부수분보유량, 피부의 산성도, 경피수분증발량에 대한 효과를 측정한 결과, 본 발명의 락토바실러스 람노서스 균주를 유크림에 접종하여 배양한 유크림 발효액을 제형 총중량의 75 중량% + 공액리놀레산 20 중량%로 제조한 로션이 락토바실러스 람노서스 MRS 배지 배양액 등과 비교하여 유의적인 피부수분보유량의 향상, 피부의 pH수치 감소, 경피수분증발량의 감소 효과를 나타냄을 확인하였다(도 2, 표 3 내지 표 5 참조). In a specific embodiment of the present invention, the present inventors prepared a lotion formulation comprising Lactobacillus rhamnosus culture and conjugated linoleic acid, and then measured the effect on the skin moisture retention, skin acidity, transdermal moisture evaporation of the formulation. , A lotion prepared with 75% by weight of the total weight of the formulation + 20% by weight of the conjugated linoleic acid was lactobacillus rhamnosus MRS medium culture, etc. It was confirmed that the skin moisture retention, the skin pH value reduction, the effect of reducing the transdermal moisture evaporation (see Fig. 2, Tables 3 to 5).
또한, 본 발명자들은 다양한 락토바실러스 람노서스 균주를 이용하여 제조된 유크림 발효액의 아토피 피부염 치료 효과를 확인한 결과, 락토바실러스 람노서스 균주로 발효시킨 모든 유크림 발효액을 함유하는 아토피 피부염 개선용 화장료는 피부수분보유량이 증가하고, 피부의 pH수치는 감소하였으며, 경피수분증발량이 감소하는 등 아토피 피부염의 병변 발현을 억제할 뿐 아니라, 병변의 완화 및 병변 재발의 억제효과에 기여하는 것을 확인하였다(표 6 내지 표 8 참조).In addition, the present inventors confirmed the atopic dermatitis treatment effect of the milk cream fermentation broth prepared using a variety of Lactobacillus rhamnosus strains, cosmetics for improving atopic dermatitis containing all the milk cream fermentation broth fermented with Lactobacillus rhamnosus strain It was confirmed that not only inhibits the expression of atopic dermatitis, but also contributes to alleviating the lesions and suppressing the recurrence of the lesions. To Table 8).
또한, 본 발명자들은 락토바실러스 람노서스 KCTC 5033을 접종하여 발효시킨 탈지유 발효액을 1차 도포용으로, 순수 공액리놀레산(pure CLA)을 2차 도포용 제형으로 사용하여 아토피 피부염 치료 효과를 확인한 결과, 혼합물 처리군과 동일하게 유의적인 아토피 피부염 치료 효과를 나타냄을 확인하였다(표 9 내지 표 11 참조).In addition, the present inventors confirmed the therapeutic effect of atopic dermatitis by using a skim milk fermentation broth fermented with Lactobacillus rhamnosus KCTC 5033 for primary application and pure conjugated linoleic acid (pure CLA) as a secondary application formulation. It was confirmed that the same as the treatment group showed a significant atopic dermatitis treatment effect (see Table 9 to Table 11).
또한, 본 발명자들은 락토바실러스 람노서스 균주를 이용하여 제조된 유사유크림 발효액의 아토피 치료 효과를 확인하기 위하여, 락토바실러스 람노서스 균주를 이용하여 제조된 탈지유 발효액 73 중량%, 포도씨 오일 24 중량% 및 유화제 3 중량%를 혼합하여 유사유크림 발효액을 제조한 후, 공액리놀레산과 혼합하여 아토피 치료효과를 확인한 결과, 유크림 발효액을 이용한 군과 비교하여 효과가 떨어지나, 아토피 치료 효과를 일부 나타내는 것을 확인하였다(표 15 내지 표 17 참조).In addition, the present inventors 73% by weight of skim milk fermentation solution prepared using Lactobacillus rhamnosus strain, 73% by weight of grape seed oil, in order to confirm the atopy treatment effect of the pseudo-milk fermentation broth prepared using Lactobacillus rhamnosus strain After mixing 3% by weight of the emulsifier to prepare a similar milk cream fermentation broth, and then mixed with conjugated linoleic acid to confirm the atopy treatment effect, compared with the group using the milk cream fermentation broth, but the effect is reduced, it was confirmed that the atopic treatment shows some effects (See Tables 15-17).
또한, 락토바실러스 람노서스 배양액과 순수 공액리놀레산의 혼합액을 함유한 화장료 조성물의 농도의 범위를 알아보기 위해, 상기 배양액과 공액리놀레산을 다양한 첨가량으로 하여 제형을 각각 제조한 후, 아토피 치료 효과를 확인한 결과, 합리적으로 아토피 피부염을 개선하는 농도의 범위는 락토바실러스 람노서스 배양액과 순수 공액리놀레산의 혼합액의 농도가 공액리놀레산이 유지방의 2 중량%가 자체 함유된 유크림 발효액 75 중량%을 함유한 로션제형(B2)과 공액리놀레산이 유지방의 2 중량%가 자체 함유되고 유지방이 35%이상 함유된 유크림 발효액을 각각 제형 총중량의 75 중량% + 공액리놀레산 20 중량%, 즉 유크림 발효액 75 중량% + 순수 공액리놀레산 20 중량%의 제형(B3)임을 확인하였다(표 18 내지 표 20 참조).In addition, in order to determine the range of the concentration of the cosmetic composition containing a mixed solution of Lactobacillus rhamnosus culture and pure conjugated linoleic acid, the formulations were prepared using various amounts of the culture solution and conjugated linoleic acid, respectively, and then the atopic treatment effect was confirmed. The range of concentrations that reasonably improve atopic dermatitis is a lotion formulation containing 75% by weight of a milk cream fermentation broth containing 2% by weight of the conjugated linoleic acid milk fat in a mixture of Lactobacillus rhamnosus culture medium and pure conjugated linoleic acid. B2) and conjugated linoleic acid, which contains 2% by weight of milk fat and contains more than 35% milk fat, each contain 75% by weight of the total formulation weight + 20% by weight of conjugated linoleic acid, that is, 75% by weight of milk cream fermentation solution + pure conjugate It was confirmed that this formulation was 20% by weight of linoleic acid (B3) (see Tables 18-20).
또한, 본 발명자들은 본 발명의 조성물의 아토피 피부염 원인균인 황색포도상구균에 대한 항균활성을 확인한 결과, 본 발명의 락토바실러스 람노서스를 이용하여 제조된 탈지유 발효액은 황색포도상구균에 대한 유의적인 항균활성을 나타냄을 확인하였다(도 3 참조).In addition, the present inventors confirmed the antimicrobial activity against Staphylococcus aureus, a causative agent of atopic dermatitis, of the composition of the present invention, the skim milk fermentation broth prepared using Lactobacillus rhamnosus of the present invention has a significant antimicrobial activity against Staphylococcus aureus It was confirmed that it is shown (see Fig. 3).
따라서, 본 발명의 화장료 조성물은 황색포도상구균에 대한 항균활성이 높을 뿐 아니라, 아토피 피부염에서 주로 나타나는 피부 건조증, 소양증, 습진 및 염증성 피부병변 및 아급성 병변인 삼출, 가피를 동반한 구진과 인설, 만성 병변인 태선화 등의 병변의 완화 및 재발의 억제효과와 이에 상응하는 알레르기성 피부염의 병변 완화와 피부수분보유량의 향상, 피부의 pH수치 감소, 경피수분증발량의 감소 효과를 나타내므로, 아토피 피부염 예방, 억제 및 개선용 화장료 조성물로 유용하게 사용될 수 있다.
Therefore, the cosmetic composition of the present invention not only has high antibacterial activity against Staphylococcus aureus, but also skin dryness, pruritus, eczema and inflammatory skin lesions and subacute lesions such as exudation and peeling, papules and skin, which are mainly found in atopic dermatitis. Atopic dermatitis is prevented because it shows the effect of alleviating and recurring the lesions such as thyroiditis, which is a chronic lesion, and correspondingly alleviating the lesions of allergic dermatitis, improving skin moisture retention, decreasing skin pH, and transdermal moisture evaporation. It can be usefully used as a cosmetic composition for inhibiting and improving.
본 발명에 따른 화장료 조성물은 용액, 현탁액, 유탁액, 페이스트, 겔, 크림, 로션, 파우더, 비누, 계면활성제-함유 클렌징, 오일, 분말 파운데이션, 유탁액 파운데이션, 왁스 파운데이션, 스프레이 및 이들의 혼합물로 구성된 군으로부터 선택되는 제형을 가질 수 있다.The cosmetic composition according to the invention is composed of solutions, suspensions, emulsions, pastes, gels, creams, lotions, powders, soaps, surfactant-containing cleansing, oils, powder foundations, emulsion foundations, wax foundations, sprays and mixtures thereof. It may have a formulation selected from the group consisting of.
본 발명에 따른 화장료 조성물은 당업계에서 통상적으로 제조되는 어떠한 제형으로도 제조될 수 있으며, 예를 들어, 용액, 현탁액, 유탁액, 페이스트, 겔, 크림, 로션, 파우더, 비누, 계면활성제-함유 클렌징, 오일, 분말 파운데이션, 유탁액 파운데이션, 왁스 파운데이션 및 스프레이 등으로 제형화 될 수 있으나, 이에 한정되는 것은 아니다. 보다 상세하게는, 본 발명의 조성물이 화장료 조성물로 사용될 때에는 화장수, 에멀젼, 크림, 에센스, 젤, 팩 및 클렌징크림으로부터 선택되는 기초 화장료; 화운데이션 등의 메이크업 화장료로 구성되는 군으로부터 선택되는 제형으로 제조될 수 있다.Cosmetic compositions according to the invention can be prepared in any formulations conventionally prepared in the art and include, for example, solutions, suspensions, emulsions, pastes, gels, creams, lotions, powders, soaps, surfactant-containing It may be formulated as a cleansing, oil, powder foundation, emulsion foundation, wax foundation and spray, but is not limited thereto. More specifically, when the composition of the present invention is used as a cosmetic composition, a basic cosmetic selected from lotion, emulsion, cream, essence, gel, pack and cleansing cream; It may be prepared in a formulation selected from the group consisting of makeup cosmetics such as foundation.
본 발명의 제형이 페이스트, 크림 또는 겔인 경우에는 담체 성분으로서 동물성유, 식물성유, 왁스, 파라핀, 전분, 트라칸트, 셀룰로오스 유도체, 폴리에틸렌 글리콜, 실리콘, 벤토나이트, 실리카, 탈크 또는 산화아연 등이 이용될 수 있다.When the formulation of the present invention is a paste, cream or gel, animal oils, vegetable oils, waxes, paraffins, starches, trachants, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicas, talc or zinc oxide may be used as carrier components. Can be.
본 발명의 제형이 파우더 또는 스프레이인 경우에는 담체 성분으로서 락토스, 탈크, 실리카, 알루미늄 히드록시드, 칼슘 실리케이트 또는 폴리아미드 파우더가 이용될 수 있고, 특히 스프레이인 경우에는 추가적으로 클로로플루오로히드로카본, 프로판/부탄 또는 디메틸 에테르와 같은 추진체를 포함할 수 있다.When the formulation of the present invention is a powder or a spray, lactose, talc, silica, aluminum hydroxide, calcium silicate or polyamide powder may be used, in particular in the case of a spray, additionally chlorofluorohydrocarbon, propane Propellant such as butane or dimethyl ether.
본 발명의 제형이 용액 또는 유탁액인 경우에는 담체 성분으로서 용매, 용해화제 또는 유탁화제가 이용되고, 예컨대 물, 에탄올, 이소프로판올, 에틸 카보네이트, 에틸 아세테이트, 벤질 알코올, 벤질 벤조에이트, 프로필렌글리콜, 1,3-부틸글리콜 오일, 글리세롤 지방족 에스테르, 폴리에틸렌 글리콜 또는 소르비탄의 지방산 에스테르가 있다.When the formulation of the present invention is a solution or emulsion, a solvent, solubilizer or emulsifier is used as the carrier component, such as water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1 Fatty acid esters of, 3-butylglycol oil, glycerol aliphatic ester, polyethylene glycol or sorbitan.
본 발명의 제형이 현탁액인 경우에는 담체 성분으로서 물, 에탄올 또는 프로필렌 글리콜과 같은 액상의 희석제, 에톡실화 이소스테아릴 알코올, 폴리옥시에틸렌 소르비톨 에스테르 및 폴리옥시에틸렌 소르비탄 에스테르와 같은 현탁제, 미소 결정성 셀룰로오스, 알루미늄 메타히드록시드, 벤토나이트, 아가 또는 트라칸트 등이 이용될 수 있다.When the formulation of the present invention is a suspension, liquid carrier diluents such as water, ethanol or propylene glycol, suspending agents such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol esters and polyoxyethylene sorbitan esters, and microcrystals are used as carrier components. Soluble cellulose, aluminum metahydroxy, bentonite, agar or tracant and the like can be used.
본 발명의 제형이 계면활성제 함유 클렌징인 경우에는 담체 성분으로서 지방족 알코올 설페이트, 지방족 알코올 에테르 설페이트, 설포숙신산 모노에스테르, 이세티오네이트, 이미다졸리늄 유도체, 메틸타우레이트, 사르코시네이트, 지방산 아미드 에테르 설페이트, 알킬아미도베타인, 지방족 알코올, 지방산 글리세리드, 지방산 디에탄올아미드, 식물성 유, 라놀린 유도체 또는 에톡실화 글리세롤 지방산 에스테르 등이 이용될 수 있다.When the formulation of the present invention is a surfactant-containing cleansing, the carrier component is aliphatic alcohol sulfate, aliphatic alcohol ether sulfate, sulfosuccinic acid monoester, isethionate, imidazolinium derivative, methyltaurate, sarcosinate, fatty acid amide ether Sulfates, alkylamidobetaines, aliphatic alcohols, fatty acid glycerides, fatty acid diethanolamides, vegetable oils, lanolin derivatives or ethoxylated glycerol fatty acid esters and the like can be used.
또한 본 발명의 화장료 조성물은 각각의 제형에 상기 기재한 성분들 이외에 일반 피부화장료에 배합되는 유분, 물, 계면활성제, 보습제, 저급알코올, 증점제, 킬레이트제, 색소, 방부제, 또는 향료 등을 필요에 따라 적절히 배합하여 사용할 수 있다.In addition, the cosmetic composition of the present invention requires oils, water, surfactants, humectants, lower alcohols, thickeners, chelating agents, pigments, preservatives, or fragrances, etc., which are formulated in general skin cosmetics in addition to the components described above in each formulation. It can mix | blend suitably according to the use.
예컨대, 유연화장수는 본 발명에 따른 균주 배양액 이외에 다가알콜류(프로필렌글리콜, 글리세린 등) 1∼10 중량% 및 계면활성제(폴리에틸렌올레일에테르, 폴리옥시에틸렌 경화피마자유 등) 0.05∼2 중량%를 함유하도록 제조할 수 있다. 또한, 영양화장수 및 영양크림은 본 발명에 따른 균주 배양액 이외에 오일류(스쿠알란, 바셀린, 옥틸도데칸올 등) 5∼20 중량% 및 왁스성분(세탄올, 스테아릴알콜, 밀납 등) 3∼15 중량%를 함유하도록 제조할 수 있으며, 에센스는 본 발명에 따른 균주 배양액 이외에 글리세린, 프로필렌글리콜 등의 다가알콜류 5∼30 중량%를 함유하여 제조할 수 있다. 마사지 크림은 본 발명에 따른 균주 배양액 이외에 유동파라핀, 바셀린, 이소노닐이소노나노에이트 등의 오일 30∼70 중량%를 함유하여 제조되며, 팩은 본 발명에 따른 균주 배양액 이외에 폴리비닐알콜 5∼20 중량%를 함유하는 필 오프(peel off) 팩 또는 일반유화형 화장료에 본 발명에 따른 균주 배양액 이외에 카올린, 탈크, 산화아연, 이산화티탄 등의 안료가 5∼30 중량% 함유된 워시오프(wash off) 팩으로 제조할 수 있다.
For example, flexible softener contains 1 to 10% by weight of polyhydric alcohols (propylene glycol, glycerin, etc.) and 0.05 to 2% by weight of surfactants (polyethylene oleyl ether, polyoxyethylene hydrogenated castor oil, etc.) in addition to the strain culture medium according to the present invention. Can be prepared. In addition, nutrient cosmetics and nourishing cream is 5 to 20% by weight of oils (squalane, petrolatum, octyldodecanol, etc.) and wax components (cetanol, stearyl alcohol, beeswax, etc.) in addition to the strain culture medium according to the present invention It may be prepared to contain%, essence may be prepared by containing 5 to 30% by weight of polyhydric alcohols such as glycerin, propylene glycol in addition to the strain culture medium according to the present invention. Massage cream is prepared by containing 30 to 70% by weight of oil, such as liquid paraffin, petrolatum, isononyl isononanoate in addition to the strain culture medium according to the present invention, the pack is polyvinyl alcohol 5-20 in addition to the strain culture medium according to the present invention Wash off containing 5-30% by weight of pigments such as kaolin, talc, zinc oxide and titanium dioxide in addition to the strain culture medium according to the present invention in a peel-off pack or a general emulsion cosmetic containing weight% ) Pack.
또한, 본 발명은 락토바실러스 람노서스 배양액 및 공액리놀레산을 유효성분으로 함유하는 아토피 피부염 예방, 억제 및 개선용 피부 외용제를 제공한다.The present invention also provides a topical skin preparation for the prevention, inhibition and improvement of atopic dermatitis containing Lactobacillus rhamnosus culture and conjugated linoleic acid as an active ingredient.
본 발명의 락토바실러스 람노서스 배양액 및 공액리놀레산을 포함하는 혼합물은 황색포도상구균에 대한 항균활성이 높을 뿐 아니라, 아토피 피부염에서 주로 나타나는 피부 건조증, 소양증, 습진 및 염증성 피부병변 및 아급성 병변인 삼출, 가피를 동반한 구진과 인설, 만성 병변인 태선화 등의 병변의 완화 및 재발의 억제효과와 이에 상응하는 알레르기성 피부염의 병변 완화와 피부수분보유량의 향상, 피부의 pH수치 감소, 경피수분증발량의 감소 효과를 나타내므로, 아토피 예방, 억제 및 개선용 피부 외용제로 유용하게 사용될 수 있다.The mixture containing the Lactobacillus rhamnosus culture medium and conjugated linoleic acid of the present invention has high antibacterial activity against Staphylococcus aureus, as well as exudative skin dryness, pruritus, eczema and inflammatory skin lesions and subacute lesions, which are mainly found in atopic dermatitis. Alleviation of lesions such as papules and scales accompanied by crusts, and thyroiditis, chronic lesions, and the inhibition of recurrence and the corresponding alleviation of allergic dermatitis, improvement of skin moisture retention, reduction of skin pH, and transdermal moisture evaporation Since it shows an effect, it can be usefully used as an external preparation for skin for prevention, inhibition and improvement of atopy.
상기 피부 외용제는 락토바실러스 람노서스 배양액 및 공액리놀레산을 피부에 도포하거나, 락토바실러스 람노서스 배양액을 피부에 도포한 후, 공액리놀레산을 도포할 수 있다.The external preparation for skin may apply lactobacillus rhamnosus culture and conjugated linoleic acid to the skin, or apply lactobacillus rhamnosus culture to the skin and then apply conjugated linoleic acid.
아토피 피부염 예방, 억제 및 개선을 위하여, 적합한 외용제형을 선택하는 것이 중요하다. 따라서, 락토바실러스 람노서스 배양액 및 공액리놀레산이 환부에 효과적으로 적용될 수 있도록 연고제로 제조할 수 있다. 상기 연고제는 본 발명의 락토바실러스 람노서스 배양액 및 공액리놀레산 혼합물을 무기물질과 배합한 다음, 이를 지용성 기제로 코팅하여 제조한다. 상기 무기물질은 항균성, 소염효과, 표피재생 효과 등이 우수한 소재를 사용하는 것이 바람직하고, 이들의 구체적인 예로는 산화아연, 탄산아연, 산화철 등이 있다. 또한, 수용성 물질인 본 발명의 피부질환 치료용 약학적 조성물을 안전하게 함침할 수 있는 세라믹 담체를 추가로 사용하는 것이 바람직하다. 상기 세라믹 담체로는 제올라이트, 활석, 석고, 모려분 및 이들의 혼합물이 바람직하게 사용된다. 이러한 세라믹 담체는 수용성 성분의 함침성이 우수하여 피부에 수용성 성분의 공급을 원활히 할 수 있다.
In order to prevent, suppress and ameliorate atopic dermatitis, it is important to select a suitable external formulation. Therefore, Lactobacillus rhamnosus culture and conjugated linoleic acid can be prepared as an ointment so that it can be effectively applied to the affected area. The ointment is prepared by combining the Lactobacillus rhamnosus culture solution and conjugated linoleic acid mixture of the present invention with an inorganic material, and then coating it with a fat-soluble base. The inorganic material is preferably used a material having excellent antibacterial, anti-inflammatory effect, epidermal regeneration effect, and specific examples thereof include zinc oxide, zinc carbonate, iron oxide. In addition, it is preferable to further use a ceramic carrier that can safely impregnate the pharmaceutical composition for treating skin diseases of the present invention, which is a water-soluble substance. As the ceramic carrier, zeolite, talc, gypsum, seed powder and mixtures thereof are preferably used. Such a ceramic carrier is excellent in the impregnation of the water-soluble component can facilitate the supply of the water-soluble component to the skin.
또한, 본 발명은 락토바실러스 람노서스 균주를 포함하는 우유 발효액을 유효성분으로 함유하는 아토피 피부염 예방, 억제 및 개선용 화장료 조성물을 제공한다.The present invention also provides a cosmetic composition for preventing, inhibiting and improving atopic dermatitis, which contains a milk fermentation broth comprising Lactobacillus rhamnosus strain as an active ingredient.
아울러, 본 발명은 락토바실러스 람노서스 균주를 포함하는 우유 발효액을 유효성분으로 함유하는 아토피 피부염 예방, 억제 및 개선용 피부 외용제를 제공한다.In addition, the present invention provides a skin external preparation for preventing, inhibiting and improving atopic dermatitis, which contains a milk fermentation broth including Lactobacillus rhamnosus strain as an active ingredient.
상기 우유 발효액은 유크림 발효액인 것이 바람직하다.The milk fermentation broth is preferably a milk cream fermentation broth.
상기 락토바실러스 람노서스 균주를 포함하는 유크림 발효액은 하기와 같이 제조되는 것이 바람직하나 이에 한정되지 않는다:The milk cream fermentation broth comprising the Lactobacillus rhamnosus strain is preferably prepared as follows, but is not limited thereto.
1) 락토바실러스 람노서스를 전배양하는 단계;1) preculturing Lactobacillus rhamnosus;
2) 상기 전배양된 락토바실러스 람노서스 균주를 유크림에 접종하고 본 배양하여 배양액인 유크림 발효액을 제조하는 단계.2) inoculating the pre-cultivated Lactobacillus rhamnosus strain in the milk cream and culturing to prepare a milk cream fermentation broth as a culture medium.
상기 유크림 발효액은 공액리놀레산을 자체 포함하는 것이 바람직하고, 유크림 발효액 전체 100 중량부에 대하여, 1 내지 3 중량부 포함하는 것이 바람직하다.
The milk cream fermentation broth preferably contains conjugated linoleic acid per se, and preferably contains 1 to 3 parts by weight based on 100 parts by weight of the whole milk cream fermentation broth.
본 발명의 구체적인 실시예에서, 본 발명자들은 락토바실러스 람노서스 균주를 포함하는 유크림 발효액의 성분을 분석한 결과, 상기 유크림 발효액의 유지방에는 공액리놀레산이 포함되어 있는 것을 확인하였다(도 1 참조).In a specific embodiment of the present invention, the present inventors analyzed the components of the milk cream fermentation broth containing the Lactobacillus rhamnosus strain, it was confirmed that the milk fat of the milk cream fermentation broth contains conjugated linoleic acid (see Figure 1) .
또한, 락토바실러스 람노서스 균주를 포함하는 유크림 발효액의 아토피 치료 효과를 확인한 결과, 상기 락토바실러스 람노서스 균주를 포함하는 유크림 발효액은 피부수분보유량의 향상, 피부의 pH수치 감소, 경피수분증발량의 감소 효과를 나타내므로, 아토피 피부염 예방, 억제 및 개선용 화장료 조성물 또는 아토피 피부염 예방, 억제 및 개선용 피부 외용제로 유용하게 사용될 수 있다(표 3 내지 표 5 참조).
In addition, as a result of confirming the atopy treatment effect of the milk cream fermentation broth containing the Lactobacillus rhamnosus strain, the milk cream fermentation broth containing the Lactobacillus rhamnosus strain improved skin moisture retention, reduced skin pH value, transdermal moisture evaporation amount Since it shows a reducing effect, it can be usefully used as a cosmetic composition for preventing, inhibiting and improving atopic dermatitis or as an external preparation for skin for preventing, suppressing and improving atopic dermatitis (see Tables 3 to 5).
이하, 본 발명을 실시예 및 실험예에 의해 상세히 설명한다.Hereinafter, the present invention will be described in detail by Examples and Experimental Examples.
단, 하기 실시예 및 실험예는 본 발명의 예시하는 것일 뿐, 본 발명의 내용이 하기 실시예 및 실험예에 한정되는 것은 아니다.
However, the following Examples and Experimental Examples are only illustrative of the present invention, and the content of the present invention is not limited to the following Examples and Experimental Examples.
<< 실시예Example 1> 1> 락토바실러스Lactobacillus 람노서스Rhamnosus 균주 및 이의 배양액의 준비 Preparation of strains and cultures thereof
MRS 배지 1ℓ에 전배양한 락토바실러스 람노서스(Lactobacillus rhamnosus) 균주(기탁번호 KCTC 5033) 1× 106 cfu/㎖를 접종한 후, 항온 37℃ 배양기에서 72시간 배양하여, MRS 균주 배양액을 수득하였다. After inoculating 1 × 10 6 cfu / ml of Lactobacillus rhamnosus strain (Accession No. KCTC 5033) precultured in 1 L of MRS medium, the cells were cultured in a constant temperature 37 ° C. incubator for 72 hours to obtain an MRS strain culture solution. .
그런 다음, 상기 락토바실러스 람노서스 MRS 배양액을 제형 총 중량의 75 중량%로 함유한 로션 제형을 제조하였다(표 1).Then, a lotion formulation was prepared containing the Lactobacillus rhamnosus MRS culture at 75 wt% of the total weight of the formulation (Table 1).
<< 실시예Example 2> 2> 락토바실러스Lactobacillus 람노서스Rhamnosus 균주를 이용한 우유 발효액의 제조 Preparation of Milk Fermentation Broth Using Strains
유지방이 3% 이하로 함유된 우유 1ℓ에 전배양한 락토바실러스 람노서스 균주(기탁번호 KCTC 5033) 1× 106 cfu/㎖를 접종한 후, 항온 37℃ 배양기에서 72시간 배양하여, 우유 발효액을 제조하였다.
아울러, 상기 우유 또는 우유 발효액을 제형 총 중량의 75 중량%로 함유한 로션 제형을 상기 <실시예 1>과 동일한 방법으로 제조하였다.
In addition, a lotion formulation containing 75% by weight of the milk or milk fermentation broth was prepared in the same manner as in <Example 1>.
<< 실시예Example 3> 3> 락토바실러스Lactobacillus 람노서스Rhamnosus 균주를 이용한 Using strain 유크림Milk cream 발효액의 제조 Preparation of Fermentation Broth
유지방이 35% 이상 함유된 유크림에 1ℓ에 전배양한 락토바실러스 람노서스 균주(기탁번호 KCTC 5033) 1× 106 cfu/㎖를 접종한 후, 항온 37℃ 배양기에서 72시간 배양하여, 유크림 발효액을 수득하였다.
아울러, 상기 유크림 또는 유크림 발효액을 제형 총 중량의 75 중량%로 함유한 로션 제형을 상기 <실시예 1>과 동일한 방법으로 제조하였다.In addition, a lotion formulation containing 75% by weight of the milk cream or milk cream fermentation broth was prepared in the same manner as in <Example 1>.
한편, 한국기능식품연구원에 의뢰하여 상기 유크림 및 유크림 발효액에 대한 지방산 검사를 수행하였으며, 공액리놀레산의 함유량은 함유 유지방과 지방산 합산 총량의 2.0 중량% 이상인 것을 확인하였다.
On the other hand, commissioned by the Korea Functional Food Research Institute was carried out a fatty acid test for the milk cream and milk cream fermentation broth, it was confirmed that the content of the conjugated linoleic acid is at least 2.0% by weight of the total amount of milk fat and fatty acids containing.
<< 실시예Example 4> 4> 락토바실러스Lactobacillus 람노서스Rhamnosus 균주를 이용한 Using strain 유크림Milk cream 발효액 및 Fermentation broth and 공액리놀레산을Conjugated linoleic acid 포함하는 조성물의 제조 Preparation of the composition comprising
상기 <실시예 3>에서 제조한 유크림 발효액을 제형 총중량의 75 중량% + 공액리놀레산 20 중량%로 제조한 로션제형을 제조하였다(표 2).The lotion formulation of the milk cream fermentation broth prepared in <Example 3> was prepared with 75% by weight of the total weight of the formulation + 20% by weight of conjugated linoleic acid (Table 2).
<< 실험예Experimental Example 1> 아토피 피부염 시험대상자의 선정 1> Selection of atopic dermatitis test subjects
임상 모집공고를 통하여 모집된 아토피 피부염 병변이 있는 참가희망자 중 한국인 아토피 피부염의 진단기준(박영립. 한국인 아토피 피부염의 진단기준. 대한피부과학회지. 2005;43(10):113.)에 의해 주 진단기준 중 적어도 2개 이상, 보조 진단기준 중 4가지 이상에 해당하며 6개월 이상 간헐적 또는 지속적으로 아토피 피부염 증상을 보인 참가 희망자를 1차 선정하고, 이들 중 6개월 이내에 아토피 피부염 치료를 위해 국소 및 전신 스테로이드, 면역 조절 및 억제제, 항히스타민제나 이에 준하는 치료를 받은 경험이 있는 사람을 제외한 참가희망자를 최종 시험대상자로 선정하였다. 아울러, 시험기간은 총 6주(42일)간으로 하였다.
Criteria for Diagnosing Korean Atopic Dermatitis Among the Participants with Atopic Dermatitis Recruited through Clinical Recruitment (Park, Young-Rip. Diagnosis Criteria for Korean Atopic Dermatitis. Journal of the Korean Dermatological Association, 2005; 43 (10): 113.) At least two of them, and at least four of the secondary diagnostic criteria, were selected as candidates for intermittent or persistent symptoms of atopic dermatitis for more than six months, and among them, local and systemic steroids for the treatment of atopic dermatitis within six months. Participants were selected as the final subjects, except those who had experience with immunomodulatory and inhibitors, antihistamines or similar treatments. In addition, the test period was 6 weeks (42 days).
<실험예 2> 아토피 치료 효과 확인 방법Experimental Example 2 Confirmation Method of Atopy Treatment Effect
피부 병변의 정확한 상태를 측정하기 위하여 항온 항습 조건을 실내온도 20~25℃, 실내습도 40~60%로 설정한 피부측정실에서 비침습적 피부측정장비인 MPA580(Multi Probe Adapter system, C+K Electronic GmbH, Cologne, Germany)을 이용하여 기계적 측정을 실시하였다. 시험대상자는 병변 부위의 정확한 평가를 위해 피부측정실 입실 12시간 전부터는 시험 화장품 도포를 금지하였으며, 입실 후 약 30분간 안정을 취하게 한 후 측정을 하였다.MPA580 (Multi Probe Adapter system, C + K Electronic GmbH), a non-invasive skin measurement device, is used in the skin measurement room where the constant temperature and humidity conditions are set at room temperature 20-25 ° C and room humidity 40-60% to measure the exact condition of skin lesions , Cologne, Germany) was used for mechanical measurements. Subjects were prohibited from applying the
또한, 피부측정은 시험 전후 총 2회에 걸쳐 실시하였고, 보다 객관적인 결과를 위해 측정자 2인이 동일한 방법으로 측정하였다. 피부측정은 피부수분보유량(skin surface hydration, SSH), 경피수분증발량(transepidermal water loss, TEWL), 피부의 산성도(pH)를 시험 전 시험대상자의 병변부위 중 중증도가 가장 심한 부위를 지정하여 측정하고, 개인별로 표시해두었다가 시험 전후 동일 병변부위를 측정하여 객관적인 효과를 평가하였다.In addition, the skin measurement was carried out twice before and after the test, for two objectives were measured by the same method. Skin measurement measures skin surface hydration (SSH), transepidermal water loss (TEWL), and acidity of skin (pH) by designating the most severe site of lesion before subject. In addition, objective effects were evaluated by measuring the same lesion site before and after the test.
아울러, 참여한 시험대상자의 병변 부위를 시험 전후 디지털 카메라(SAMSUNG, VLUU PL150)를 이용하여 총2회 촬영하였다. 객관적인 결과를 얻기 위하여 기계적 측정부위와 동일한 병변 부위를 지정된 장소에서 동일 촬영자 1인이 촬영하였다.
In addition, the lesions of the participants were taken twice before and after the test using digital cameras (SAMSUNG, VLUU PL150). To obtain objective results, the same lesion was photographed by the same photographer at the designated location.
<< 실험예Experimental Example 3> 3> 피부수분보유량Skin moisture (( SSHSSH ) 확인) Confirm
상기 <실시예 1> 내지 <실시예 4>에서 제조한 로션 제형을 상기 <실험예 1>에서 선정한 아토피 피부염 시험대상자의 병변 부위에 하루 2회, 42일간 도포한 후, 피부수분보유량의 변화를 확인하였다.After applying the lotion formulations prepared in <Example 1> to <Example 4> to the lesion site of the atopic dermatitis test subject selected in <Experimental Example 1> twice a day for 42 days, the change in skin moisture retention was Confirmed.
그 결과, 하기 표 3에 나타낸 바와 같이, 시험 전후 피부수분보유량은 각각 락토바실러스 람노서스 균주 MRS 배양액을 함유한 로션(C)과 우유를 함유한 로션(A1)이 각각 약 2%, 약 1%로 감소 경향을 보인 반면, 우유 발효액을 함유한 로션(A2)은 약 5%, 유크림을 함유한 로션(B1)은 약 6% 각각 증가 경향을 보였고, 유크림 발효액을 함유한 로션(B2)이 약 22% 유의한 증가, 유크림 발효액을 제형 총중량의 75 중량% + 공액리놀레산 20 중량%로 제조한 로션(B3)이 약 40% 유의적으로 증가된 것을 확인하였다(표 3).
As a result, as shown in Table 3 below, the skin moisture retention before and after the test was about 2% and 1% for the lotion (C) containing the Lactobacillus rhamnosus strain MRS and the lotion (A1) containing the milk, respectively. While milk lotion (A2) containing lotion (A2) and milk cream lotion (B1) tended to increase by about 6%, lotion containing milk cream fermentation (B2) About 22% significant increase, lotion (B3) prepared with milk cream fermentation broth 75% by weight of the formulation + 20% by weight conjugated linoleic acid was found to increase by about 40% significantly (Table 3).
<< 실험예Experimental Example 4> 피부 산성도(pH) 확인 4> Check skin acidity (pH)
아토피 피부염 병변 피부는 비병변 피부보다 피부의 pH가 더 높게 나타나며, 소양증이 심할수록 피부는 알칼리성으로 변해 피부 pH가 증가한다. 그러므로 시험 전에 비해 피부의 pH수치가 낮아지면 피부의 pH안정도가 높은 것으로 볼 수 있다.Atopic dermatitis lesion skin has a higher pH of the skin than non-lesion skin. The more severe the pruritus, the more the skin turns alkaline and the skin pH increases. Therefore, if the pH value of the skin is lower than before the test, the pH stability of the skin can be seen as high.
이에, 상기 <실험예 3>과 동일한 방법으로 아토피 피부염 병변 부위에서 피부의 산성도(pH)의 변화를 확인하였다. Thus, in the same manner as in <Experimental Example 3> it was confirmed the change in the acidity (pH) of the skin at the atopic dermatitis lesion site.
그 결과, 하기 표 4에 나타낸 바와 같이, 우유를 함유한 로션(A1)은 피부의 산성도가 약 8% 유의적으로 상승한 반면, 락토바실러스 람노서스 균주 MRS 배양액을 함유한 로션(C)은 약 1%, 우유 발효액을 함유한 로션(A2)은 약 3% 각각 감소 경향을, 유크림을 함유한 로션(B1)은 약 5% 감소, 유크림 발효액을 함유한 로션(B2)은 약 6% 유의한 감소, 유크림 발효액을 제형 총중량의 75 중량% + 공액리놀레산 20 중량%로 제조한 로션제형(B3)이 약 11%로 피부의 pH수치가 유의적인 감소를 보였다. 또한, 발효하지 않은 멸균 유크림을 함유한 로션(B1)의 pH수치의 감소 경향을 보아 수분베이스(유지방 함유된 우유 및 유크림) 제형이 중요함을 알 수 있다.As a result, as shown in Table 4, the lotion (A1) containing milk significantly increased the acidity of the skin by about 8%, while the lotion (C) containing Lactobacillus rhamnosus strain MRS culture was about 1%. %, Lotion (A2) containing milk fermentation tended to decrease by about 3%, lotion (B1) containing milk cream decreased by about 5%, lotion (B2) containing milk cream fermentation (B2) One decrease, the lotion formulation (B3) prepared with milk cream fermentation broth at 75% by weight of the formulation + 20% by weight of conjugated linoleic acid showed a significant decrease in skin pH. In addition, the tendency of the pH value of the lotion (B1) containing sterile milk cream that has not been fermented shows that the moisture base (milk-containing milk and milk cream) formulation is important.
따라서, 락토바실러스 람노서스로 발효시킨 우유 발효액(A2)와 유크림 발효액(B2)을 함유한 로션과 유크림 발효액을 제형 총중량의 75 중량% + 공액리놀레산 20 중량%로 제조한 로션(B3)이 피부의 pH안정화를 유도하는데도 우수함을 확인하였다(표 4).
Therefore, a lotion containing milk fermentation broth (A2) fermented with Lactobacillus rhamnosus and milk cream fermentation broth (B2) and a lotion containing milk cream fermentation broth (75% by weight + 20% by weight of conjugated linoleic acid) were prepared. It was confirmed that the skin is also excellent in inducing pH stabilization (Table 4).
<< 실험예Experimental Example 5> 5> 경피수분증발량Percutaneous moisture evaporation (( TEWLTEWL ) 확인) Confirm
상기 <실험예 3>과 동일한 방법으로 경피수분증발량의 변화를 확인하였다.In the same manner as in <Experimental Example 3> it was confirmed the change of transdermal moisture evaporation.
그 결과, 하기 표 5에 나타낸 바와 같이, 본 발명의 유크림 발효액을 제형 총중량의 75 중량% + 공액리놀레산 20 중량%로 제조한 로션(B3)이 약 41% 감소하였고, 유크림 발효액을 함유한 로션(B2)의 경피수분증발량이 약 32%로 유의적으로 감소한 것을 볼 수 있으며, 우유 발효액을 함유한 로션(A2)은 약 12% 감소 경향을 보인 반면, 락토바실러스 람노서스 배양액을 함유한 로션(C) 및 우유를 함유한 로션(A1), 유크림을 함유한 로션(B1)은 각각 약 8%, 약 6%, 약 16% 경피수분증발량이 증가 경향을 보여, 유크림 발효액을 제형 총중량의 75중량% + 공액리놀레산 20중량%로 제조한 로션(B3)과 유크림 발효액을 함유한 로션(B2)이 경피수분증발량을 감소시키는데 월등히 우수함을 확인하였다(표 5). 따라서 유크림 발효액을 제형 총중량의 75 중량% + 공액리놀레산 20 중량%로 제조한 로션(B3)과 유크림 발효액을 함유한 로션(B2)이 아토피 피부염의 병변 발현을 억제할 뿐 아니라, 병변의 완화 및 병변 재발의 억제효과에 기여하는 것을 확인하였다.
As a result, as shown in Table 5 below, the lotion (B3) prepared with the milk cream fermentation broth of the present invention at 75% by weight of the formulation + 20% by weight of the conjugated linoleic acid was reduced by about 41%. It can be seen that the transdermal moisture evaporation of the lotion (B2) was significantly reduced to about 32%, and the lotion containing milk fermentation (A2) tended to decrease by about 12%, while the lotion containing Lactobacillus rhamnosus culture was (C) and milk lotion (A1) and milk cream lotion (B1) tended to increase about 8%, about 6%, and about 16% transdermal moisture evaporation, respectively. The lotion (B3) prepared with 75% by weight of + 20% by weight of conjugated linoleic acid and lotion containing milk cream fermentation solution (B2) were found to be excellent in reducing transdermal moisture evaporation (Table 5). Therefore, lotion (B3) prepared with milk cream fermentation broth (75% by weight of the total formulation + 20% by weight of conjugated linoleic acid) and lotion with milk cream fermentation broth (B2) not only suppress the expression of atopic dermatitis, but also alleviate the lesion. And it was confirmed that it contributes to the inhibitory effect of lesion recurrence.
<<
실험예Experimental Example
6> 다양한 6> various
락토바실러스Lactobacillus
람노서스Rhamnosus
균주를 이용하여 제조된 Prepared using strain
유크림Milk cream
발효액의 아토피 치료 효과 확인 Confirmation of atopy treatment effect of fermentation broth
<6-1> 다양한 <6-1> various 락토바실러스Lactobacillus 람노서스Rhamnosus 균주를 이용한 Using strain 유크림Milk cream 발효액의 제조 Preparation of Fermentation Broth
유지방이 35% 이상 함유된 유크림에 1ℓ에 전배양한 락토바실러스 람노서스 KCTC 5033(B2), KCTC 3237(D1), KCTC 5046(D2) KCTC 5510(D3), KCCM 11320(D4), KCCM 32823(D5), KCCM 32826(D6), KCCM 40069(D7), ATCC 9595(D8), ATCC 14957(D9), ATCC 21052(D10), KCTC 10965BP(D11) 또는 RA-32(D12) 1× 106 cfu/㎖를 각각 접종한 후, 항온 37℃ 배양기에서 72시간 배양하여, 유크림 발효액을 제조하였다.Lactobacillus rhamnosus KCTC 5033 (B2), KCTC 3237 (D1), KCTC 5046 (D2) KCTC 5510 (D3), KCCM 11320 (D4), KCCM 32823 (D5), KCCM 32826 (D6), KCCM 40069 (D7), ATCC 9595 (D8), ATCC 14957 (D9), ATCC 21052 (D10), KCTC 10965BP (D11) or RA-32 (D12) 1 × 10 6 After inoculating each cfu / ml, and incubated for 72 hours in a constant temperature 37 ℃ incubator to prepare a milk cream fermentation broth.
아울러, 유크림 발효액을 제형 총 중량의 75 중량%로 함유한 로션 제형을 상기 <실시예 1>과 동일한 방법으로 제조하였다.
In addition, a lotion formulation containing the milk cream fermentation broth at 75% by weight of the formulation was prepared in the same manner as in <Example 1>.
<6-2> 피부수분보유량 확인<6-2> Skin moisture retention check
상기 <실험예 3>과 동일한 방법으로 상기 <6-1>에서 제조한 유크림 발효액을 함유한 로션 제형을 도포한 후, 피부수분보유량의 변화를 측정하였다.After applying the lotion formulation containing the milk cream fermentation broth prepared in the above <6-1> in the same manner as in <Experimental Example 3>, the change in skin moisture retention was measured.
그 결과, 하기 표 6에 나타낸 바와 같이, 락토바실러스 람노서스 KCTC 5033(B2)이 약 22% 유의하게 증가하여, 약 22%로 유의하게 증가한 KCTC 5510(D3)과 함께 가장 높은 증가율을 보였으며, KCTC 3237(D1)은 약 18% 증가, KCTC 5046(D2)은 약 20% 증가, KCCM 11320(D4)이 약 19% 유의한 증가, KCCM 32823(D5)은 약 17% 증가, KCCM 32826(D6)이 약 20% 유의한 증가, KCCM 40069(D7)가 약 15% 유의한 증가, ATCC 9595(D8)는 약 13% 유의한 증가, ATCC 14957(D9)은 약 20% 유의한 증가, ATCC 21052(D10)는 약 17% 유의한 증가, KCTC 10965BP(D11)는 약 18% 증가를 하였으며, RA-32(D12)도 약 17% 피부수분보유량이 증가해 락토바실러스 람노서스 균주로 발효시킨 유크림 발효액을 함유한 로션제형이 피부수분보유량을 증가시키는 것을 확인하였다(표 6).
As a result, as shown in Table 6, Lactobacillus rhamnosus KCTC 5033 (B2) significantly increased about 22%, showing the highest increase rate with KCTC 5510 (D3) significantly increased to about 22%, KCTC 3237 (D1) increased approximately 18%, KCTC 5046 (D2) increased approximately 20%, KCCM 11320 (D4) increased approximately 19%, KCCM 32823 (D5) increased approximately 17%, KCCM 32826 (D6) ) Approximately 20% significant increase, KCCM 40069 (D7) approximately 15% significant increase, ATCC 9595 (D8) approximately 13% significant increase, ATCC 14957 (D9) approximately 20% significant increase, ATCC 21052 (D10) increased by about 17%, KCTC 10965BP (D11) increased by about 18%, and RA-32 (D12) also increased by about 17% in skin moisture retention, which was fermented with Lactobacillus rhamnosus strain. It was confirmed that lotion formulations containing fermentation broth increased skin moisture retention (Table 6).
<6-3> 피부의 산성도 확인<6-3> Check the acidity of the skin
상기 <실험예 4>와 동일한 방법으로 상기 <6-1>에서 제조한 유크림 발효액을 함유한 로션 제형을 도포한 후, 피부의 산성도 변화를 측정하였다.After applying the lotion formulation containing the milk cream fermentation broth prepared in the above <6-1> in the same manner as in <Experimental Example 4>, the change in the acidity of the skin was measured.
그 결과, 하기 표 7에 나타낸 바와 같이, 락토바실러스 람노서스 KCTC 5033(B2)이 약 6% 유의한 감소를 보였으며, KCTC 3237(D1)이 약 2% 감소, KCTC 5046(D2)은 약 5% 감소, KCTC 5510(D3)은 약 4% 감소, KCCM 32823(D5)은 약 3% 감소, KCCM 32826(D6)이 약 3% 감소, KCCM 40069(D7)는 약 1% 감소, ATCC 9595(D8)는 약 3% 감소, ATCC 14957(D9)이 약 4% 감소, ATCC 21052(D10)가 약 4% 감소, KCTC 10965BP(D11)는 약 6% 감소, RA-32(D12) 또한 약 5% 피부의 pH수치가 감소하여 변화율이 없었던 KCCM 11320(D4)을 제외한 균주들이 락토바실러스 람노서스 균주로 발효시킨 유크림 발효액이 피부의 pH안정도의 증가에 기여하는 것을 확인하였다(표 7).
As a result, as shown in Table 7, Lactobacillus rhamnosus KCTC 5033 (B2) showed a significant decrease of about 6%, KCTC 3237 (D1) about 2% decrease, KCTC 5046 (D2) about 5% % Decrease, KCTC 5510 (D3) decreases approximately 4%, KCCM 32823 (D5) decreases approximately 3%, KCCM 32826 (D6) decreases approximately 3%, KCCM 40069 (D7) decreases approximately 1%, ATCC 9595 ( D8) is reduced by about 3%, ATCC 14957 (D9) is reduced by about 4%, ATCC 21052 (D10) is reduced by about 4%, KCTC 10965BP (D11) is reduced by about 6%, RA-32 (D12) is also about 5% It was confirmed that the milk cream fermentation broth fermented with Lactobacillus rhamnosus strains except KCCM 11320 (D4), which had no change rate due to the decrease of the pH value of the skin (Table 7).
<6-4> 경피수분증발량 확인<6-4> Confirmation of transdermal moisture evaporation
상기 <실험예 5>와 동일한 방법으로 상기 <6-1>에서 제조한 유크림 발효액을 함유한 로션을 도포한 후, 경피수분증발량을 측정하였다.After applying the lotion containing the milk cream fermentation broth prepared in the above <6-1> in the same manner as in <Experimental Example 5>, the amount of transdermal moisture evaporation was measured.
그 결과, 하기 표 8에 나타낸 바와 같이, 유크림 발효액의 로션제형의 경피수분증발량은 락토바실러스 람노서스 KCTC 5033(B2)가 약 32% 유의하게 감소하여 가장 높은 감소율을 보였으며, KCTC 3237(D1)이 약 15% 감소, KCTC 5046(D2)은 약 25% 감소, KCTC 5510(D3)은 약 24% 유의한 감소, KCCM 11320(D4)은 약 19% 감소, KCCM 32823(D5)은 약 15% 감소, KCCM 32826(D6)은 약 26% 감소, KCCM 40069(D7)는 약 14% 감소, ATCC 9595(D8)는 약 28% 감소, ATCC 14957(D9)은 약 31% 유의한 감소, ATCC 21052(D10)는 약 28% 감소, KCTC 10965BP(D11)는 약 27% 유의한 감소, RA-32(D12)도 약 24% 감소해 락토바실러스 람노서스 균주로 발효시킨 유크림 발효액이 경피수분증발량의 감소에 기여하는 것을 확인하였다(표 8).As a result, as shown in Table 8, the transdermal moisture evaporation of the lotion formulation of the milk cream fermentation broth showed the highest decrease rate by about 32% of Lactobacillus rhamnosus KCTC 5033 (B2), KCTC 3237 (D1) ) Approximately 15% less, KCTC 5046 (D2) approximately 25% less, KCTC 5510 (D3) approximately 24% less, KCCM 11320 (D4) approximately 19% less, KCCM 32823 (D5) approximately 15% % Decrease, KCCM 32826 (D6) about 26% decrease, KCCM 40069 (D7) about 14% decrease, ATCC 9595 (D8) about 28% decrease, ATCC 14957 (D9) about 31% significant decrease, ATCC The amount of transdermal moisture evaporated from fermented milk cream fermented with Lactobacillus rhamnosus strain decreased 21052 (D10) by about 28%, KCTC 10965BP (D11) by about 27%, and RA-32 (D12) by about 24%. It was confirmed to contribute to the reduction of (Table 8).
따라서 락토바실러스 람노서스 균주로 발효시킨 모든 유크림 발효액을 함유하는 아토피피부염 개선용 화장료는 피부수분보유량이 모두 증가하고, 피부의 pH수치는 거의 감소하였으며, 경피수분증발량도 모두 감소하는 등 아토피 피부염의 병변 발현을 억제할 뿐 아니라, 병변의 완화 및 병변 재발의 억제효과에 기여하는 것을 확인하였다.
Therefore, atopic dermatitis improvement cosmetics containing all the milk cream fermentation broth fermented with Lactobacillus rhamnosus strain have all skin moisture retention, skin pH value decreased, and transdermal moisture evaporation all decreased. In addition to inhibiting the expression of the lesions, it was confirmed that they contribute to the alleviation of the lesion and the inhibitory effect of the recurrence of the lesion.
<<
실험예Experimental Example
7> 7>
락토바실러스Lactobacillus
람노서스Rhamnosus
KCTCKCTC
5033을 접종하여 발효시킨 탈지유 발효액을 1차 도포용으로, 순수 The skim milk fermentation broth fermented by inoculation with 5033 is pure for primary application.
공액리놀레산을Conjugated linoleic acid
2차 도포용 제형으로 사용하여 아토피피부염 치료 효과 확인 Confirmation effect of atopic dermatitis by using as a second application formulation
<7-1> <7-1> 락토바실러스Lactobacillus 람노서스를Rhamnosus 이용한 탈지유 발효액(skim milk)의 제조 Preparation of skim milk fermentation (skim milk) using
탈지유 1ℓ에 락토바실러스 람노서스 균주(기탁번호 KCTC 5033) 1 × 106 cfu/㎖를 접종한 후, 항온 37℃ 배양기에서 72시간 배양하여, 탈지유 발효액을 수득하였다.
1 L of skim milk was inoculated with 1 × 10 6 cfu / ml of Lactobacillus rhamnosus strain (Accession No. KCTC 5033), and then cultured in a constant temperature 37 ° C. incubator for 72 hours to obtain a skim milk fermentation broth.
<7-2> 피부수분보유량 측정<7-2> Skin moisture retention measurement
상기 <7-1>에서 제조한 탈지유 발효액을 아토피 피부염 병변 부위에 1차 도포한 후, 순수한 공액리놀레산을 2차 도포(E)한 다음, 상기 <실험예 3>과 동일한 방법으로 피부수분보유량의 변화를 확인하였다.The skim milk fermentation broth prepared in the above <7-1> was first applied to the atopic dermatitis lesion, and then pure conjugated linoleic acid was secondly applied (E), and then the skin moisture retention amount was measured in the same manner as in <Experimental Example 3>. Change was confirmed.
그 결과, 하기 표 9에 나타낸 바와 같이, 탈지유 발효액을 1차 도포한 동일한 아토피 피부염 병변 부위에 순수공액리놀레산을 2차 도포한 결과, 피부수분보유량이 약 15% 증가하는 것을 확인하였다(표 9).
As a result, as shown in Table 9 below, as a result of second application of pure conjugated linoleic acid to the same atopic dermatitis lesion site to which skim milk fermentation broth was first applied, it was confirmed that the skin moisture retention increased by about 15% (Table 9). .
<7-3> 피부의 산성도 확인<7-3> Check the acidity of the skin
상기 <7-1>에서 제조한 탈지유 발효액을 아토피 피부염 병변 부위에 1차 도포한 후, 순수한 공액리놀레산을 2차 도포(E)한 다음, 상기 <실험예 4>와 동일한 방법으로 피부의 산성도 변화를 측정하였다.After applying the skim milk fermentation broth prepared in the above <7-1> to the atopic dermatitis lesion site, pure conjugated linoleic acid was secondly applied (E), and the acidity of the skin was changed in the same manner as in <
그 결과, 하기 표 10에 나타낸 바와 같이, 탈지유 발효액을 1차 도포한 동일한 아토피 피부염 병변 부위에 순수공액리놀레산을 2차 도포한 결과, 피부의 pH 수치가 9% 감소하여 피부의 pH 안정도가 향상되는 것을 확인하였다(표 10).
As a result, as shown in Table 10 below, when pure conjugated linoleic acid was secondarily applied to the same atopic dermatitis lesion site where the skim milk fermentation broth was first applied, the pH value of the skin was reduced by 9% to improve the pH stability of the skin. It was confirmed (Table 10).
<7-4> 경피수분증발량 확인<7-4> Confirmation of transdermal moisture evaporation
상기 <7-1>에서 제조한 탈지유 발효액을 아토피 피부염 병변 부위에 1차 도포한 후, 순수한 공액리놀레산을 2차 도포(E)한 다음, 상기 <실험예 5>와 동일한 방법으로 경피수분증발량의 변화를 측정하였다.The skim milk fermentation broth prepared in the above <7-1> was first applied to the atopic dermatitis lesion, and then pure conjugated linoleic acid was secondly applied (E), followed by the same method as in <
그 결과, 하기 표 11에 나타낸 바와 같이, 탈지유 발효액을 1차 도포한 동일한 아토피 피부염 병변 부위에 순수공액리놀레산을 2차 도포한 결과, 경피수분증발량이 약 31% 감소되는 것을 확인하였다(표 11).As a result, as shown in Table 11 below, as a result of second application of pure conjugated linoleic acid to the same atopic dermatitis lesion site to which skim milk fermentation broth was first applied, it was confirmed that the amount of transdermal moisture evaporation decreased by about 31% (Table 11). .
따라서, 락토바실러스 람노서스 KCTC 5033을 접종하여 발효시킨 탈지유 발효액을 제형의 1차 도포용 제형으로, 순수리놀레산(pure CLA)을 2차 도포용 제형으로 피부에 사용한 경우, 피부수분보유량이 증가하고, 피부의 pH수치는 감소하였으며, 경피수분증발량이 감소하는 등 아토피 피부염의 병변 발현을 억제할 뿐 아니라, 병변의 완화 및 병변 재발의 억제효과에 기여하는 것을 확인하였다.
Therefore, when the skim milk fermentation broth inoculated with Lactobacillus rhamnosus KCTC 5033 is used as the primary application formulation of the formulation, and pure linoleic acid (pure CLA) is used as the secondary application formulation, the skin moisture retention increases, It was confirmed that the pH value of the skin was decreased and the amount of transdermal moisture evaporation was reduced, which not only suppressed the expression of atopic dermatitis, but also contributed to alleviating the lesion and suppressing the recurrence of the lesion.
<<
실험예Experimental Example
8> 8>
락토바실러스Lactobacillus
람노서스Rhamnosus
균주를 이용하여 제조된 Prepared using strain
유사유크림Similar oil cream
발효액의 아토피 치료 효과 확인 Confirmation of atopy treatment effect of fermentation broth
<8-1> <8-1> 유사유크림Similar oil cream 발효액의 제조 Preparation of Fermentation Broth
상기 <7-1>에서 제조한 탈지유 발효액을 제형 총중량의 73 중량%를 함유한 발효액을 하기 표 12와 같이 제조하여, 유사유크림 발효액을 수득하였다(표 12). 그럼 다음, 상기 유사유크림 발효액을 제형 총 중량의 75 중량%로 함유한 로션 제형(F1)을 하기 표 13의 방법으로 제조하였다(표 13). 아울러, 상기 제조한 유사유크림 발효액(75 중량%)과 공액리놀레산(20 중량%)으로 로션제형(F2)을 제조하였다(표 14).The skim milk fermentation broth prepared in <7-1> was prepared as a fermentation broth containing 73 wt% of the total weight of the formulation as shown in Table 12 to obtain a pseudo milk cream fermentation broth (Table 12). Then, a lotion formulation (F1) containing the yolk cream fermentation broth at 75 wt% of the total weight of the formulation was prepared by the method of Table 13 below (Table 13). In addition, a lotion formulation (F2) was prepared from the prepared similar oil cream fermentation broth (75 wt%) and conjugated linoleic acid (20 wt%) (Table 14).
<8-2> <8-2> 피부수분보유량Skin moisture 확인 Confirm
상기 <실험예 3>과 동일한 방법으로 상기 <8-1>에서 제조한 유사유크림 발효액을 포함하는 로션제형 F1 및 F2를 각각 도포한 후, 피부수분보유량의 변화를 측정하였다.In the same manner as in <Experimental Example 3>, after applying the lotion formulations F1 and F2 containing the pseudo-oil fermentation broth prepared in the above <8-1>, respectively, the change in skin moisture retention was measured.
그 결과, 하기 표 15에 나타낸 바와 같이, 시험 전후 피부수분보유량은 유사유크림 발효액 75 중량%을 함유한 로션(F1)이 약 16% 유의한 증가, 유사유크림 발효액을 제형 총중량의 75 중량% + 공액리놀레산 20 중량%로 제조한 로션(F2)이 약 19%로 유의하게 증가시키는 것을 확인하였다(표 15).
As a result, as shown in Table 15 below, the skin moisture retention before and after the test was increased by about 16% in the lotion (F1) containing 75% by weight of milk cream fermentation broth. + Lotions (F2) prepared with 20% by weight of conjugated linoleic acid were found to significantly increase to about 19% (Table 15).
<8-3> 피부의 산성도 확인<8-3> Check the acidity of the skin
상기 <실험예 4>와 동일한 방법으로 상기 <8-1>에서 제조한 유사유크림 발효액을 포함하는 로션제형 F1 및 F2를 각각 도포한 후, 피부의 산성도의 변화를 측정하였다.In the same manner as in <Experimental Example 4>, after applying the lotion formulations F1 and F2 containing the pseudo-oil fermentation broth prepared in the above <8-1>, respectively, the change in acidity of the skin was measured.
그 결과, 하기 표 16에 나타낸 바와 같이, 시험 전후 피부의 pH안정도가 다소 낮기는 하나, 유사유크림 발효액 75 중량%을 함유한 로션(F1)이 약 0.2%, 유사유크림 발효액을 제형 총중량의 75 중량% + 공액리놀레산 20 중량%로 제조한 로션(F2)이 약 3% 피부의 pH를 감소시키는 것을 확인하였다(표 16).
As a result, as shown in Table 16 below, although the pH stability of the skin before and after the test was somewhat low, the lotion (F1) containing 75% by weight of milk cream fermentation broth was about 0.2%, and the milk cream fermentation solution was similar to the total weight of the formulation. A lotion (F2) prepared with 75% by weight + 20% by weight conjugated linoleic acid was found to reduce the pH of the skin by about 3% (Table 16).
<8-4> 경피수분증발량 확인<8-4> Confirmation of transdermal moisture evaporation
상기 <실험예 5>와 동일한 방법으로 상기 <8-1>에서 제조한 유사유크림 발효액을 도포한 후, 경피수분증발량의 변화를 측정하였다.After applying the pseudo-milk cream fermentation broth prepared in <8-1> in the same manner as in <Experimental Example 5>, the change in transdermal moisture evaporation was measured.
그 결과, 하기 표 17에 나타낸 바와 같이, 시험 전후 경피수분증발량의 변화가 유사유크림 발효액 75 중량%을 함유한 로션(F1)이 약 9%, 유사유크림 발효액을 제형 총중량의 75 중량% + 공액리놀레산 20 중량%로 제조한 로션(F2)이 약 20%로 경피수분증발량을 감소시키는 것을 확인하였다(표 17).As a result, as shown in Table 17 below, the change in transdermal moisture evaporation amount before and after the test was about 9% for lotion (F1) containing 75% by weight of milk cream fermentation broth, and 75% by weight of the total weight of milk cream fermentation solution + Lotion (F2) prepared with 20% by weight of conjugated linoleic acid was found to reduce transdermal moisture evaporation to about 20% (Table 17).
따라서, 락토바실러스 람노서스 KCTC 5033으로 발효시킨 유사유크림 발효액(skim milk 73 중량% + 포도씨 오일 24 중량% + 유화제 3 중량%로 제조한 유사유크림) 제형 총중량의 75 중량%을 함유한 로션(F1)과 유사유크림 발효액을 제형 총중량의 75 중량% + 공액리놀레산 20 중량%로 제조한 로션(F2)을 피부에 도포한 경우, 상기 공액리놀레산이 유지방의 2 중량%가 자체 함유된 유지방 35%이상 함유된 유크림 발효액을 75 중량% 함유한 로션제형(B2)과 유크림 발효액을 제형 총중량의 75 중량% + 공액리놀레산 20 중량%로 제조한 로션(B3)에 비해 효과가 떨어지기는 하나, 피부수분보유량을 증가시키고, 피부의 pH수치를 감소시키며, 경피수분증발량을 감소시켜, 아토피 피부염의 병변 발현을 억제할 뿐 아니라, 병변의 완화 및 병변 재발의 억제효과에 기여할 수 있음을 확인하였다.
Thus, a lotion containing 75% by weight of the total weight of the milk cream fermentation broth (73% by weight of milk milk + 24% by weight of grape seed oil + 3% by weight of emulsifier) formulated with Lactobacillus rhamnosus KCTC 5033 When the lotion (F2) prepared from F1) and the similar milk cream fermentation broth (75% by weight of the total weight of the formulation + 20% by weight of the conjugated linoleic acid) was applied to the skin, the milk fat containing 2% by weight of the milk containing the conjugated linoleic acid was 35%. Lotion formulation containing more than 75% by weight of the milk cream fermentation broth (B2) and milk cream fermentation broth is less effective than the lotion (B3) prepared with 75% by weight of the formulation + 20% by weight conjugated linoleic acid, but It is confirmed that it can increase the water retention, decrease the skin pH level, and reduce the transdermal moisture evaporation, which not only suppress the expression of atopic dermatitis, but also contribute to the alleviation of the lesion and the inhibition of the recurrence of the lesion. The.
<실험예 9> 공액리놀레산의 화장료 조성물 내, 농도 범위 확인<
<9-1> <9-1> 락토바실러스Lactobacillus 람노서스Rhamnosus 배양액과 순수 Medium and pure water 공액리놀레산의Conjugated linoleic acid 혼합액을 다양한 성분비로 포함하는 조성물의 제조 Preparation of composition containing mixed liquid in various component ratios
락토바실러스 람노서스 배양액과 순수 공액리놀레산의 혼합액을 함유한 화장료 조성물의 농도의 범위를 알아보기 위해, 유지방 3%이하 함유(공액리놀레산은 유지방의 2 중량% 함유)된 우유 발효액 75 중량%가 함유된 로션제형(A2, CLA 0.045%), 유지방 35%(공액리놀레산은 유지방의 2 중량% 함유)이상 함유된 유크림 발효액 75 중량%가 함유된 로션제형(B2, CLA 0.525%)과 유크림 발효액(공액리놀레산은 유지방의 2 중량% 함유)을 제형 총중량의 75 중량% + 순수 공액리놀레산 20 중량%로 제조한 로션제형(B3, CLA 20.525%), 상기 탈지유 발효액을 1차 도포용으로, 순수 공액리놀레산을 2차 도포용 제형으로 사용한, 즉 탈지유 발효액 100 중량% + 순수 공액리놀레산 100 중량%로 도포한 방법(E, CLA 100%), 상기 락토바실러스 람노서스 KCTC 5033을 접종하여 발효시킨 유사유크림 발효액(skim milk 73 중량% + 포도씨 오일 24 중량% + 유화제 3 중량%로 제조한 유사 유크림)의 제형 총중량 75 중량% + 공액리놀레산 20 중량%, 즉 유사유크림 발효액 75 중량% + 순수 공액리놀레산 20 중량%로 제조한 로션제형(F2, CLA 20%), 상기 락토바실러스 람노서스 KCTC 5033을 접종하여 발효시킨 탈지유 발효액 99.9 중량% + 순수 공액리놀레산 0.1 중량%로 제조한 토너 제형(G1, CLA 0.1%), 상기 락토바실러스 람노서스 KCTC 5033을 접종하여 발효시킨 탈지유 발효액 75 중량% + 순수 공액리놀레산 20 중량%로 제조한 로션 제형(G2, CLA 20%), 상기 락토바실러스 람노서스 KCTC 5033을 접종하여 발효시킨 유사유크림 발효액(skim milk 64 중량% + 포도씨 오일 35 중량% + 유화제 1 중량%로 제조한 유사유크림)의 제형 총중량 49 중량% + 공액리놀레산 46 중량%, 즉 유사유크림 발효액 49 중량% + 순수 공액리놀레산 46 중량%로 제조한 로션제형(G3, CLA 46%), 상기 락토바실러스 람노서스 KCTC 5033을 접종하여 발효시킨 유사유크림 발효액(skim milk 64 중량% + 포도씨 오일 35 중량% + 유화제 1 중량%로 제조한 유사 유크림)의 제형 총중량 35 중량% + 공액리놀레산 60 중량%, 즉 유사유크림 발효액 35 중량% + 순수 공액리놀레산 60 중량%로 제조한 크림 제형(G4, CLA 60%)에 대한 아토피 피부염 완화 시험을 상기 <실험예 3> 내지 <실험예 5>에 개시된 방법을 이용하여 확인하였다.
To determine the range of the concentration of the cosmetic composition containing a mixture of Lactobacillus rhamnosus culture and pure conjugated linoleic acid, containing 75% by weight of milk fermented broth containing 3% or less milk (conjugated linoleic acid contained 2% by weight of milk fat). Lotion formulation (A2, CLA 0.045%), milk fat 35% (conjugated linoleic acid contains 2% by weight of milk fat) lotion formulation (B2, CLA 0.525%) and milk cream fermentation broth (75% by weight) Conjugated linoleic acid containing 2% by weight of milk fat) lotion formulation (B3, CLA 20.525%) prepared with 75% by weight of the total weight of the formulation + 20% by weight of pure conjugated linoleic acid, pure conjugated linoleic acid for the first application Was used as a secondary coating formulation, i.e., 100% by weight of skim milk fermentation broth + 100% by weight of pure conjugated linoleic acid (E, CLA 100%), and similar milk cream fermentation broth inoculated with Lactobacillus rhamnosus KCTC 5033. (ski m 73% by weight of milk + 24% by weight of grape seed oil + 3% by weight of similar milk cream formulated with 3% by weight of emulsifier) 75% by weight of formulation + 20% by weight of conjugated linoleic acid, i.e. Lotion formulation prepared in% (F2, CLA 20%), toner formulation prepared with 99.9% by weight of skim milk fermentation broth fermented with the Lactobacillus rhamnosus KCTC 5033 + 0.1% by weight of pure conjugated linoleic acid (G1, CLA 0.1%) , A lotion formulation prepared with 75% by weight of skim milk fermentation broth fermented with Lactobacillus rhamnosus KCTC 5033 + 20% by weight of pure conjugated linoleic acid (G2, CLA 20%), the Lactobacillus rhamnosus KCTC 5033 fermented Formulation of 49% by weight of milk cream fermentation (64% by weight of milk milk + 35% by weight of grape seed oil + 1% by weight of emulsifier) formulation total weight + 46% by weight of conjugated linoleic acid, ie 49% by weight of milk cream fermentation + Pure conjugated linol A lotion formulation (G3, CLA 46%) prepared with 46% by weight of resan, and a milk cream fermentation solution (skim milk 64% by weight + 35% by weight of grape seed oil + 1% by weight of emulsifier) inoculated with the Lactobacillus rhamnosus KCTC 5033. Formulations of similar milk cream) 35% by weight + 60% by weight conjugated linoleic acid, ie 35% by weight similar milk cream fermentation solution + 60% by weight of pure conjugated linoleic acid, atopy for cream formulation (G4, CLA 60%) The dermatitis alleviation test was confirmed using the method described in <Experimental Example 3> to <Experimental Example 5>.
<9-2> 피부수분보유량 확인<9-2> Skin moisture retention check
상기 <실험예 3>과 동일한 방법으로 피부수분보유량의 변화를 측정하였다.The change in skin moisture retention was measured in the same manner as in <Experimental Example 3>.
그 결과, 표 18에 나타낸 바와 같이, B3가 약 40%로 피부수분보유량이 유의하게 증가하여 증가율이 가장 높게 나타났으며, G4가 약 25% 증가, B2가 약 22% 유의한 증가, G2가 약 21% 증가, F2가 약 19% 유의한 증가, G3이 약 16% 증가, E가 약 15% 증가, G1이 약 14% 증가, A2가 약 5%로 증가하여 모두 피부수분보유량이 증가됨을 확인하였다(표 18).
As a result, as shown in Table 18, B3 was approximately 40%, and the skin moisture retention was significantly increased, showing the highest increase, G4 was increased by about 25%, B2 was increased by about 22%, and G2 was increased. About 21% increase, F2 about 19% significant increase, G3 about 16% increase, E about 15% increase, G1 about 14% increase, A2 about 5%, all increase skin moisture retention. It was confirmed (Table 18).
<9-3> 피부의 산성도 확인<9-3> Check the acidity of the skin
상기 <실험예 4>와 동일한 방법으로 피부의 산성도 변화를 측정하였다.The acidity change of the skin was measured in the same manner as in <Experimental Example 4>.
그 결과, 하기 표 19에 나타낸 바와 같이, B3가 약 11%로 피부의 pH수치가 유의하게 감소하여 감소율이 가장 높게 나타났고, E가 약 9% 감소, B2가 약 6% 유의한 감소, G3가 약 5% 감소, G2가 약 4% 감소, F2와 A2가 각각 약 3% 감소, G4가 약 2% 감소, G1이 약 1%로 피부의 pH수치가 감소해 피부의 pH 안정도 향상에 기여하는 것을 확인하였다(표 19).
As a result, as shown in Table 19, B3 was about 11%, the pH value of the skin was significantly decreased, the reduction rate was the highest, E about 9% decrease, B2 about 6% significant decrease, G3 About 5% decrease, G2 about 4%, F2 and A2 about 3%, G4 about 2%, G1 about 1%, reducing the pH value of the skin, contributing to improved skin pH stability It was confirmed that (Table 19).
<9-4> 경피수분증발량 확인<9-4> Confirmation of transdermal moisture evaporation
상기 <실험예 5>와 동일한 방법으로 경피수분증발량의 변화를 측정하였다.The change of transdermal moisture evaporation was measured in the same manner as in <
그 결과, 상기 <실험예 5>와 동일한 방법으로 경피수분증발량의 변화를 확인한 결과, 하기 표 20에 나타낸 바와 같이, B3가 약 41%로 감소율이 가장 높게 나타났고, B2가 약 32% 유의한 감소를 나타내었으며, E가 약 31% 감소, G3가 약 25% 유의한 감소, F2가 약 20% 감소, G4가 약 18% 감소, A2와 G2가 각각 약 12% 감소해, G1이 1%로 경미하게 증가한 것을 제외하고 모두 경피수분증발량이 감소되는 것을 확인하였다(표 20).
As a result, as a result of confirming the change of transdermal moisture evaporation in the same manner as in <Experimental Example 5>, as shown in Table 20, B3 is the highest decrease rate to about 41%, B2 is about 32% significant A decrease of about 31% for E, about 25% for G3, about 20% for F2, about 18% for G4, and about 12% for A2 and G2, and 1% for G1 Except for the slight increase in transdermal moisture evaporation was confirmed to decrease (Table 20).
결론적으로, 락토바실러스 람노서스 배양액과 순수 공액리놀레산의 혼합액의 농도가 공액리놀레산이 유지방의 2 중량% 자체 함유된 유크림 발효액 75 중량%을 함유한 로션제형(B2, CLA 0.525%), 공액리놀레산이 유지방의 2 중량% 자체 함유된 유크림 발효액을 각각 제형 총중량의 75 중량% + 순수 공액리놀레산 20 중량%로 제조한 로션제형(B3, CLA 20.525%), 탈지유 발효액 100 중량%로 1차 도포 후 순수 공액리놀레산 100 중량%로 2차 도포한 방법(E, CLA 100%) 뿐만 아니라, 락토바실러스 람노서스 배양액과 순수 공액리놀레산의 혼합액의 농도가 공액리놀레산이 유지방의 2 중량% 자체 함유된 우유발효액 75 중량%을 함유한 로션제형(A2, CLA 0.045%), 탈지유 발효액 99.9 중량% + 순수 공액리놀레산 0.1 중량%(G1, CLA 0.1%), 탈지유 발효액 75 중량% + 순수 공액리놀레산 20 중량%(G2, CLA 20%), 유사유크림 발효액 75 중량% + 순수 공액리놀레산 20 중량%로 제조한 로션제형(F2, CLA 20%), 탈지유 발효액 49 중량% + 순수 공액리놀레산 46 중량%로 제조한 로션제형(G3, CLA 46%), 탈지유 발효액 35 중량% + 순수 공액리놀레산 60 중량%로 제조한 크림 제형(G4, CLA 60%)의 경우도 피부수분보유량이 증가하고, 피부의 pH수치의 감소, G1이외는 경피수분증발량이 감소하는 등 아토피 피부염의 병변 발현을 억제할 뿐 아니라, 병변의 완화 및 병변 재발의 억제효과에 기여하는 것으로 나타나, 락토바실러스 람노서스 배양액과 공액리놀레산의 혼합액의 조성물로써의 농도 범위(각 총 중량의 0.1-99.9 중량%를 함유한 화장료 조성물 단, 발효배지가 유지방 3%이하 함유된 우유일 경우는 각 총중량 0.04-99.9 중량%)에 관한 충족조건을 달성할 뿐 아니라, 이 중 합리적으로 아토피 피부염을 개선하는 농도의 범위는 락토바실러스 람노서스 배양액과 순수 공액리놀레산의 혼합액의 농도가 공액리놀레산이 유지방의 2 중량%가 자체 함유된 유크림 발효액 75 중량%을 함유한 로션제형(B2)과 공액리놀레산이 유지방의 2 중량%가 자체 함유되고 유지방 35%이상 함유된 유크림 발효액을 각각 제형 총중량의 75 중량% + 공액리놀레산 20 중량%, 즉 유크림 발효액 75 중량% + 순수 공액리놀레산 20 중량%의 제형(B3)임을 확인하였다.
In conclusion, the lotion formulation (B2, CLA 0.525%), conjugated linoleic acid contained a mixture of Lactobacillus rhamnosus culture medium and pure conjugated linoleic acid containing 75% by weight of milk cream fermented with 2% by weight of conjugated linoleic acid itself. A lotion formulation (B3, CLA 20.525%) prepared with 2 wt% of milk fat self-containing milk cream fermentation solution, each containing 75 wt% of the total weight of the formulation + 20 wt% of pure conjugated linoleic acid, and 100 wt% of skim milk fermentation broth. In addition to the method of second coating with 100% by weight of conjugated linoleic acid (E, CLA 100%), the concentration of the mixed solution of Lactobacillus rhamnosus culture medium and pure conjugated linoleic acid was 75% by weight of the milk fermented solution containing 2% by weight of the conjugated linoleic acid milk fat. Lotion formulation containing% (A2, CLA 0.045%), skimmed milk fermented broth 99.9% by weight + pure conjugated linoleic acid 0.1% by weight (G1, CLA 0.1%), skimmed milk fermented by 75% + pure conjugated linoleic acid 20% by weight (G2, CLA 20%) , Lotion formulation made with 75% by weight of similar milk cream fermentation solution + 20% by weight of pure conjugated linoleic acid (F2, CLA 20%), Lotion formulation made with 49% by weight skim milk fermentation solution + 46% by weight of pure conjugated linoleic acid (G3, CLA 46 %), The cream formulation (G4, CLA 60%) made with 35% by weight of skim milk fermentation solution + 60% by weight of pure conjugated linoleic acid also increases the skin moisture retention, decreases the pH value of the skin, transdermal moisture evaporation except G1 In addition to reducing the expression of atopic dermatitis and reducing the expression of the atopic dermatitis, it has been shown to contribute to the alleviation of the lesion and the recurrence of the lesion, and the concentration range as a composition of the mixed solution of Lactobacillus rhamnosus culture and conjugated linoleic acid (each total weight Cosmetic composition containing 0.1-99.9% by weight of the present invention, except that if the fermentation medium is milk containing 3% or less of milk fat, it meets the requirements for the total weight of 0.04-99.9% by weight), and among them, atopic dermatologically Concentrations for improving salt range from the formulation of Lactobacillus rhamnosus culture and pure conjugated linoleic acid to a conjugated lotion formulation (B2) containing 75% by weight of a milk cream fermentation broth containing 2% by weight of conjugated linoleic acid milk fat. The milk cream fermentation broth containing 2% by weight of linoleic acid itself and containing at least 35% of the milk fat is 75% by weight of the total formulation + 20% by weight of conjugated linoleic acid, that is, 75% by weight of milk cream fermentation + 20% by weight of pure conjugated linoleic acid. It was confirmed that the formulation (B3).
<<
실험예Experimental Example
10> 10>
공액리놀레산이Conjugated
상기 <실시예 1>에서 제조한 유크림 발효액의 아토피 치료효과를 확인하기 위하여, 상기 유크림 발효액을 아토피 피부염 환자 병변 부위에 하루 2회, 42일간 도포한 후, 참여한 시험대상자의 병변 부위를 시험 전후 디지털 카메라(SAMSUNG, VLUU PL150)를 이용하여 촬영하였다. 객관적인 결과를 얻기 위하여 기계적 측정부위와 동일한 병변 부위를 지정된 촬영 장소에서 촬영자 1인이 이미지 촬영하였다.In order to confirm the atopy treatment effect of the milk cream fermentation broth prepared in <Example 1>, the milk cream fermentation broth was applied twice a day for 42 days to the lesion site of atopic dermatitis patients, and then the lesion site of the participating test subject was tested. The images were taken using a post-war digital camera (SAMSUNG, VLUU PL150). In order to obtain objective results, one photographer photographed the same lesion site as the mechanical measurement site at a designated location.
그 결과, 도 2에 나타낸 바와 같이, 모든 시험군에서 시험 전(before)과 비교하여 시험 후(after) 유의적인 항 아토피 효과를 나타냄을 확인하였다(도 2).
As a result, as shown in Figure 2, it was confirmed that all the test groups showed a significant anti-atopic effect after the test (before) compared with before (Fig. 2).
<실험예 11> 락토바실러스 람노서스 균주의 항균활성 확인Experimental Example 11 Confirmation of Antimicrobial Activity of Lactobacillus Rhamnosus Strains
MRS배지에서 전배양한 후 유지방이 0중량% 이하로 함유된 skim milk에서 각각 락토바실러스 람노서스 KCTC 3237, KCTC 5033, KCTC 5046, KCTC 5510, KCCM 11320, KCCM 32823, KCCM 32826, KCCM 40069, ATCC 9595, ATCC 14957, ATCC 21052, KCTC 10965BP(M21) 또는 RA-32를 발효시킨 배양액의 황색포도상구균(Staphylococcus aureus)에 대한 항균을 확인하였다.Lactobacillus rhamnosus KCTC 3237, KCTC 5033, KCTC 5046, KCTC 5510, KCCM 11320, KCCM 32823, KCCM 32826, KCCM 40069, ATCC 9595 The antimicrobial activity of Staphylococcus aureus was confirmed in the cultures fermented with ATCC 14957, ATCC 21052, KCTC 10965BP (M21) or RA-32.
구체적으로, 항균활성 측정은 paper disc법 및 적하법(dripping)으로 실시하였으며, 각 균주는 MRS배지에서 24시간 전배양한 후 skim milk에서 72시간 본배양하였으며 25℃실온에서 후배양을 하면서 24시간씩 5회에 걸쳐 항균작용에 의해 형성된 clear zone을 관찰하였다.Specifically, the antimicrobial activity was measured by paper disc method and dripping method. Each strain was pre-cultivated in MRS medium for 24 hours and then incubated for 72 hours in skim milk and after 24 hours at 25 ° C room temperature. Clear zones formed by antibacterial activity were observed five times.
그 결과, 도 3에 나타낸 바와 같이, 본 발명의 락토바실러스 람노서스 배양액은 황색포도상구균에 대해 유의적인 항균활성을 나타냄을 확인하였다(도 3).
As a result, as shown in Figure 3, it was confirmed that the Lactobacillus rhamnosus culture of the present invention showed a significant antimicrobial activity against Staphylococcus aureus (Fig. 3).
Claims (14)
A cosmetic composition for preventing, inhibiting and improving atopic dermatitis containing Lactobacillus rhamnosus culture containing at least one of milk or milk cream and conjugated linoleic acid as an active ingredient.
The method according to claim 1, wherein the Lactobacillus rhamnosus with the accession number KCTC 5033, KCTC 3237, KCTC 5046, KCTC 5510, KCTC 10965BP, KCCM 11320, KCCM 32823, KCCM 32826, KCCM 40069, ATCC 9595, ATCC 14957 and ATCC 21052 Cosmetic composition for preventing, inhibiting and improving atopic dermatitis, characterized in that the Lactobacillus rhamnosus selected from the group consisting of.
The cosmetic composition of claim 1, wherein the milk is selected from among nonfat milk, low fat, nonfat milk, or skim milk having a content of 1 part by weight or less.
[Claim 2] The cosmetic composition for preventing, inhibiting and improving atopic dermatitis according to claim 1, wherein the milk cream is a milk fat having 30% or more of milk fat separated from milk or milk, or a concentrate of milk fat formed by a milk fat barrier film. .
The cosmetic composition for preventing, inhibiting and improving atopic dermatitis according to claim 1, comprising 0.01 to 99.9 parts by weight of Lactobacillus rhamnosus culture medium and 0.1 to 99.9 parts by weight of conjugated linoleic acid, based on 100 parts by weight of the total composition.
The cosmetic composition for preventing, inhibiting and improving atopic dermatitis according to claim 1, wherein the cosmetic composition improves skin moisture retention, stabilizes skin by decreasing pH level, and reduces transdermal moisture evaporation.
The cosmetic composition for preventing, inhibiting and improving atopic dermatitis according to claim 1, wherein the cosmetic composition has antibacterial activity against Staphylococcus aureus .
The composition of claim 1 wherein the cosmetic composition is a solution, suspension, emulsion, paste, gel, cream, lotion, powder, soap, surfactant-containing cleansing, oil, powder foundation, emulsion foundation, wax foundation, spray and their Cosmetic composition for the prevention, inhibition and improvement of atopic dermatitis, characterized in that it has a formulation selected from the group consisting of a mixture of.
A topical skin preparation for preventing, inhibiting and improving atopic dermatitis, which comprises lactobacillus rhamnosus culture solution containing milk or milk cream and conjugated linoleic acid as an active ingredient.
The skin external preparation for atopic dermatitis prevention, inhibition and improvement according to claim 9, wherein the external preparation for skin is applied to the skin with Lactobacillus rhamnosus culture solution, followed by sequentially applying conjugated linoleic acid.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020160035879A KR102061387B1 (en) | 2016-03-25 | 2016-03-25 | Cosmetic composition for improving atopic dermatitis comprising Lactobacillus rhamnosus and conjugated linoleic acid |
| PCT/KR2017/003172 WO2017164681A1 (en) | 2016-03-25 | 2017-03-24 | Cosmetic composition for alleviating atopic dermatitis, containing, as active ingredients, lactobacillus rhamnosus culture solution, or lactobacillus rhamnosus culture solution and conjugated linoleic acid |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020160035879A KR102061387B1 (en) | 2016-03-25 | 2016-03-25 | Cosmetic composition for improving atopic dermatitis comprising Lactobacillus rhamnosus and conjugated linoleic acid |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20170111086A KR20170111086A (en) | 2017-10-12 |
| KR102061387B1 true KR102061387B1 (en) | 2019-12-31 |
Family
ID=59899597
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020160035879A Active KR102061387B1 (en) | 2016-03-25 | 2016-03-25 | Cosmetic composition for improving atopic dermatitis comprising Lactobacillus rhamnosus and conjugated linoleic acid |
Country Status (2)
| Country | Link |
|---|---|
| KR (1) | KR102061387B1 (en) |
| WO (1) | WO2017164681A1 (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102015180B1 (en) * | 2017-10-30 | 2019-08-27 | 건국대학교 산학협력단 | Cosmetic composition comprising the fermented milk-cream broth of lactic acid bacteria |
| WO2019059668A2 (en) * | 2017-09-22 | 2019-03-28 | 건국대학교 산학협력단 | Composition for skin, containing, as active ingredient, milk cream liquid fermented by lactic acid bacteria |
| KR101975671B1 (en) * | 2017-09-22 | 2019-05-07 | 건국대학교 산학협력단 | Composition comprising the milk-cream fermentation product of lactic acid bacteria for preventing and improving atopic dermatitis |
| GB201807576D0 (en) | 2018-05-09 | 2018-06-20 | Skinbiotherapeutics Plc | Compositions and uses thereof |
| KR102615130B1 (en) * | 2018-09-21 | 2023-12-19 | 주식회사 팜스킨 | Composition for improving atopic skin of fermented product of colostrum |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011029784A1 (en) * | 2009-09-08 | 2011-03-17 | Giuliani Spa | Probiotic lactobacillus rhamnosus strain and oral and topical uses thereof |
| KR101168169B1 (en) * | 2009-08-19 | 2012-07-24 | 남현수 | Rubus coreanus Miquel oil composition, use and preparation method thereof |
| KR101540743B1 (en) | 2014-04-28 | 2015-08-03 | 대한민국 | Producing method of conjugated linoleic acid and bean fermented food |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20110134151A (en) * | 2010-06-08 | 2011-12-14 | 주식회사 케이씨아이 | Skin inflammatory disease improving agent comprising a mixed bacterial culture, cosmetic composition and pharmaceutical composition comprising the same |
| KR101640744B1 (en) * | 2014-05-07 | 2016-07-19 | 일동제약주식회사 | Macromolecular polysaccharide binder conjugated Lactobacillus rhamnosus RHT-3201, and use thereof in prevention and treatment of atopic dermatitis |
-
2016
- 2016-03-25 KR KR1020160035879A patent/KR102061387B1/en active Active
-
2017
- 2017-03-24 WO PCT/KR2017/003172 patent/WO2017164681A1/en active Application Filing
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101168169B1 (en) * | 2009-08-19 | 2012-07-24 | 남현수 | Rubus coreanus Miquel oil composition, use and preparation method thereof |
| WO2011029784A1 (en) * | 2009-09-08 | 2011-03-17 | Giuliani Spa | Probiotic lactobacillus rhamnosus strain and oral and topical uses thereof |
| KR101540743B1 (en) | 2014-04-28 | 2015-08-03 | 대한민국 | Producing method of conjugated linoleic acid and bean fermented food |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20170111086A (en) | 2017-10-12 |
| WO2017164681A1 (en) | 2017-09-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102061387B1 (en) | Cosmetic composition for improving atopic dermatitis comprising Lactobacillus rhamnosus and conjugated linoleic acid | |
| US8951775B2 (en) | Cosmetic use of microorganisms for the treatment of oily skin | |
| KR101878069B1 (en) | Composition comprising herbal mixture extracts and hinoki oil for preventing or treating acne and atopic dermatitis | |
| KR101965482B1 (en) | Cosmetic composition for recovering damaged skin barriers and improving aged skin comprising Lactobacillus rhamnosus as an active ingredient | |
| KR100772575B1 (en) | Skin external composition containing herbal extract | |
| KR101719223B1 (en) | Cosmetic composition for promoting ceramide biosynthesis containing Panax ginseng, honey, and propolis fermented by kimchi lactic acid bacteria | |
| KR100962052B1 (en) | Cosmetic composition for improving acne containing Lactobacillus rhamnosus lactic acid strain or culture medium thereof | |
| WO2011029784A1 (en) | Probiotic lactobacillus rhamnosus strain and oral and topical uses thereof | |
| KR101064904B1 (en) | Cosmetic composition for improving acne comprising a natural extract | |
| JP2001172176A (en) | Skin improver | |
| KR102367528B1 (en) | Cosmetic composition comprising seaweed extracts | |
| US20180140646A1 (en) | Fermented composition for relieving atopic dermatitis containing natural extracts | |
| KR101851010B1 (en) | Compositions for the antiinflammatory and the antimicrobial activities | |
| CN114376928A (en) | Oil-control acne-removing skin-care composition and preparation method thereof | |
| US20080014153A1 (en) | Topical Preparation For Application To The Skin Containing Natural Oil Of The Evening Primrose (Oenothera Biennis) (=Oleum Oenotherae) And Osmolytes Originating From Extremophilic Microorganisms | |
| KR20220133136A (en) | Composition for improving acne skin comprising hemp seed extract and hemp seed oil | |
| KR101460777B1 (en) | Cosmetic composition for improving acne | |
| KR20190048933A (en) | Cosmetic Composition Comprising Extracts of Colostrum for Improving Skin Wrinkle | |
| KR101987717B1 (en) | Cosmetic composition for reducing acne and inhibiting sebum secretion containing chrysophanol, mangiferin and shikonofuran a | |
| JP3606580B2 (en) | Cosmetics | |
| KR101227590B1 (en) | Cosmetic composition comprising for improving acne | |
| KR20100101444A (en) | Cosmetic for preventing and curing acnes | |
| KR102315646B1 (en) | Skin improvement composition including Korean pine extract | |
| KR20240008176A (en) | Functional cosmetic composition comprising an extract of a novel Lactobacillus lactic acid bacteria HK9 complex ferment extracts | |
| KR101214611B1 (en) | Cosmetics composition comprising sanguinarin for preventing acne |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 20160325 |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20181001 Comment text: Request for Examination of Application Patent event code: PA02011R01I Patent event date: 20160325 Comment text: Patent Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20190829 Patent event code: PE09021S01D |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20191219 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20191224 Patent event code: PR07011E01D |
|
| PR1002 | Payment of registration fee |
Payment date: 20191224 End annual number: 3 Start annual number: 1 |
|
| PG1601 | Publication of registration | ||
| PR1001 | Payment of annual fee |
Payment date: 20220915 Start annual number: 4 End annual number: 4 |
|
| PR1001 | Payment of annual fee |
Payment date: 20241002 Start annual number: 6 End annual number: 6 |